<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="publisher-id">Therapeutics and Clinical Risk Management</journal-id><journal-title>Therapeutics and Clinical Risk Management</journal-title><issn pub-type="ppub">1176-6336</issn><issn pub-type="epub">1178-203X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18360650</article-id><article-id pub-id-type="pmc">1936359</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Raj</surname><given-names>Kavita</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mufti</surname><given-names>Ghulam J</given-names></name></contrib><aff><institution>The Department of Haematological Medicine, Kings College</institution><addr-line>London, UK</addr-line></aff></contrib-group><author-notes><corresp>Correspondence: Ghulam J Mufti Department of Haematological Medicine, Kings College Hospital, Denmark Hill, London SE59RS, UK Tel +44 20 7346 3080 Fax +44 20 7346 4980 Email: <email>ghulam.mufti@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2006</year></pub-date><pub-date pub-type="epub"><month>12</month><year>2006</year></pub-date><volume>2</volume><issue>4</issue><fpage>377</fpage><lpage>388</lpage><copyright-statement>© 2006 Dove Medical Press Limited. All rights reserved</copyright-statement><copyright-year>2006</copyright-year><abstract><p><offsets xml_i="1925" xml_f="3235" txt_i="11" txt_f="1321">The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders that manifest as bone marrow failure with the risk of life threatening infections and bleeding. A third of these patients may transform to acute leukemia. Age and co-morbidities have limited treatment in the majority to supportive care with a minority of patients eligible for the only curative modality to date, allogeneic stem cell transplantation. The advent of targeted therapy has increased the repertoire of therapeutic options. In particular the methyl transferase inhibitor 5 Azacytidine, that targets epigenetic changes in MDS, has been shown to be effective in up to 60% of patients in a Phase III randomized controlled trial comparing it with best supportive care and has been licensed by the US Food and Drug Administration for use in all subtypes of MDS. It has been shown to prolong time to leukemic transformation (21 vs 12 months with 3% transforming to leukemia p=0.0001) and is the only disease-modifying drug. Patients with monosomy 7, trisomy 8, and diploid chromosomes appear to particularly benefit with the former deriving sustained remissions. As an outpatient therapy, with an acceptable side effect profile, treatment with Azacytidine needs to be considered in all MDS patients who are eligible for treatment.</offsets></p></abstract><kwd-group><kwd>azacytidine</kwd><kwd>myelodysplastic syndromes</kwd><kwd>demethylation</kwd><kwd>methyltransferase inhibitor</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="3434" xml_f="3446" txt_i="1329" txt_f="1341">Introduction</offsets></title><p><offsets xml_i="3457" xml_f="3871" txt_i="1342" txt_f="1756">The myelodysplastic syndromes (MDS) are an acquired form of clonal stem cell disorders that manifest heterogeneously but are unified clinically by progressive bone marrow failure, susceptibility to life threatening infections, and a risk of transforming to leukemia. Although a third of patients transform to acute myeloid leukemia (AML), infection and bleeding are the commonest cause of morbidity and mortality (</offsets><xref ref-type="bibr" rid="b30"><offsets xml_i="3903" xml_f="3924" txt_i="1756" txt_f="1777">Heaney and Golde 1999</offsets></xref><offsets xml_i="3931" xml_f="4047" txt_i="1777" txt_f="1893">). MDS occurs with a frequency of 15–50 new cases per 100 000 per year and this incidence appears to be increasing (</offsets><xref ref-type="bibr" rid="b4"><offsets xml_i="4078" xml_f="4092" txt_i="1893" txt_f="1907">Aul et al 1998</offsets></xref><offsets xml_i="4099" xml_f="4196" txt_i="1907" txt_f="2004">) making it the commonest hematological malignancy along with chronic lymphocytic leukemia (CLL).</offsets></p><p><offsets xml_i="4203" xml_f="4489" txt_i="2005" txt_f="2291">Therapeutically the management of cytopenia’s and infections predominates early MDS. Treatment options such as AML induction type chemotherapy followed by an allogeneic stem cell transplantation is an option for only a minority of patients, but is the only modality that offers a cure (</offsets><xref ref-type="bibr" rid="b32"><offsets xml_i="4521" xml_f="4534" txt_i="2291" txt_f="2304">Ho et al 2004</offsets></xref><offsets xml_i="4541" xml_f="5373" txt_i="2304" txt_f="3136">). In the majority of patients the standard care is supportive in the form of blood and platelet transfusions, treatment of infective complications and administration of growth factors such as granulocyte-colony stimulating factor (G-CSF) and erythropoietin. There has been a dearth of suitable therapies for the elderly that bridged the gap between the extremes of supportive care on the one hand and stem cell transplantation on the other. The emergence of targeted therapies has rekindled interest in their application to MDS. Candidates have included the farnesyl transferase inhibitors, thalidomide and its immunomodulatory drug (IMiD) analogs such as lenalidomide and the methyltransferase inhibitors (MTI) such as Azacytidine and its analogue 5 Aza 2′ deoxycytidine in MDS. Potentially reversible silencing of genes (such as </offsets><italic><offsets xml_i="5381" xml_f="5387" txt_i="3136" txt_f="3142">CDKN2B</offsets></italic><offsets xml_i="5396" xml_f="5936" txt_i="3142" txt_f="3682">) by promoter methylation has been shown to occur in MDS and increase with disease progression. The MTIs have been shown to be demethylating agents both in vivo and in vitro and could target these changes in MDS. The MTIs are administered as outpatient therapies with proven efficacy. 5-Azacytidine, in particular, has been shown to be effective in all subtypes of MDS to prolong the time to disease progression and is the only drug in this group that has been licensed by the US Food and Drug Administration (FDA) for all subtypes of MDS (</offsets><xref ref-type="bibr" rid="b40"><offsets xml_i="5968" xml_f="5988" txt_i="3682" txt_f="3702">Kaminskas et al 2005</offsets></xref><offsets xml_i="5995" xml_f="5997" txt_i="3702" txt_f="3704">).</offsets></p><p><offsets xml_i="6004" xml_f="6139" txt_i="3705" txt_f="3840">This review aims to summarize the rationale for the use of Azacytidine and the current clinical evidence supporting its use in the MDS.</offsets></p></sec><sec><title><offsets xml_i="6161" xml_f="6182" txt_i="3842" txt_f="3863">Classification of MDS</offsets></title><p><offsets xml_i="6193" xml_f="6574" txt_i="3864" txt_f="4245">Since the risk of leukemic transformation is varied between various subgroups of MDS, various classification systems and prognostic scores have attempted to identify patients with a poor prognosis and an increased risk of leukemic transformation. The widely used French American British (FAB) classification of MDS identifies five morphological subgroups of prognostic importance (</offsets><xref ref-type="table" rid="tbl1"><offsets xml_i="6608" xml_f="6615" txt_i="4245" txt_f="4252">Table 1</offsets></xref><offsets xml_i="6622" xml_f="6625" txt_i="4252" txt_f="4255">) (</offsets><xref ref-type="bibr" rid="b5"><offsets xml_i="6656" xml_f="6674" txt_i="4255" txt_f="4273">Bennett et al 1982</offsets></xref><offsets xml_i="6681" xml_f="7110" txt_i="4273" txt_f="4702">). Patients with refractory anemia (RA) with excess blasts (RAEB) and RA with excess blasts in transformation (RAEB-t) are at a high risk of myeloid leukemic transformation (AML) and also have a shorter median survival whereas patients with RA and RARS (RA with ringed sideroblasts) have a longer survival and lower incidence of developing leukemia. The World Health Organisation (WHO) classification of MDS identifies 7 groups (</offsets><xref ref-type="table" rid="tbl2"><offsets xml_i="7144" xml_f="7151" txt_i="4702" txt_f="4709">Table 2</offsets></xref><offsets xml_i="7158" xml_f="7161" txt_i="4709" txt_f="4712">) (</offsets><xref ref-type="bibr" rid="b66"><offsets xml_i="7193" xml_f="7206" txt_i="4712" txt_f="4725">Vardiman 2002</offsets></xref><offsets xml_i="7213" xml_f="8372" txt_i="4725" txt_f="5881">). Patients with RARS and RA have only unilineage (erythroid) dysplasia with or without 15% ringed sideroblasts respectively and experience a protracted clinical course with median survivals of 5–6 years. The propensity for leukemic transformation is low in both RA (7%) and RARS (1%–2%). Refractory cytopenia with multilineage dysplasia (RCMD) and RCMD with ringed sideroblasts are characterized by bi or pancytopenia and dysplasia in ≥10% of the cells in 2 or more myeloid cell lines. Both these groups have a shorter median survival of approximately 33 months, and a frequency of leukemic transformation of 10%–13%. However patients in the RCMD group with complex karyotypes have survivals similar to those with RAEB. The WHO classification redefined AML as a group with bone marrow (BM) blasts &gt;20% and RAEB as between 5%–20% blasts with RAEB being further classified into RAEBI (5%–9% blasts) and RAEBII (10%–19% blasts). Approximately 21% of patients with RAEBI and 34% of patients with RAEBII progress to AML. The rest succumb to the effects of bone marrow failure. The median survival is approximately 18 months for RAEBI and 10 months for RAEBII (</offsets><xref ref-type="bibr" rid="b23"><offsets xml_i="8404" xml_f="8422" txt_i="5881" txt_f="5899">Germing et al 2000</offsets></xref><offsets xml_i="8429" xml_f="8571" txt_i="5899" txt_f="6041">). Patients with 5q-syndrome have a long survival and a low leukemic transformation rate. The International Prognostic Scoring System (IPSS) (</offsets><xref ref-type="table" rid="tbl3"><offsets xml_i="8605" xml_f="8612" txt_i="6041" txt_f="6048">Table 3</offsets></xref><offsets xml_i="8619" xml_f="8622" txt_i="6048" txt_f="6051">) (</offsets><xref ref-type="bibr" rid="b27"><offsets xml_i="8654" xml_f="8674" txt_i="6051" txt_f="6071">Greenberg et al 1997</offsets></xref><offsets xml_i="8681" xml_f="9032" txt_i="6071" txt_f="6422">) based on bone marrow blast percentage, cytogenetics, and number of cytopenias also identifies patients at high risk of transformation (IPSS score 1.5). These scoring systems help to individualize therapeutic decisions such as treatment with chemotherapy, allogeneic transplantation, or use of drugs like lenalidomide or methyltransferase inhibitors.</offsets></p><table-wrap id="tbl1" position="float"><label><offsets xml_i="9082" xml_f="9089" txt_i="6423" txt_f="6430">Table 1</offsets></label><caption><p><offsets xml_i="9109" xml_f="9138" txt_i="6430" txt_f="6459">The FAB classification of MDS</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="9241" xml_f="9253" txt_i="6460" txt_f="6472">FAB subgroup</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="9299" xml_f="9324" txt_i="6472" txt_f="6497">Peripheral blood criteria</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="9370" xml_f="9381" txt_i="6497" txt_f="6508">BM criteria</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9451" xml_f="9453" txt_i="6508" txt_f="6510">RA</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="9499" xml_f="9532" txt_i="6511" txt_f="6538">Blasts &lt;1%, monocytes &lt;1×10</offsets><sup><offsets xml_i="9537" xml_f="9538" txt_i="6538" txt_f="6539">9</offsets></sup><offsets xml_i="9544" xml_f="9546" txt_i="6539" txt_f="6541">/L</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="9592" xml_f="9651" txt_i="6542" txt_f="6595">Blasts &lt;5%, ringed sideroblasts &lt;15% of erythroblasts</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9706" xml_f="9710" txt_i="6596" txt_f="6600">RARS</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="9756" xml_f="9790" txt_i="6601" txt_f="6629">Blasts &lt;1%, monocytes &lt; 1×10</offsets><sup><offsets xml_i="9795" xml_f="9796" txt_i="6629" txt_f="6630">9</offsets></sup><offsets xml_i="9802" xml_f="9804" txt_i="6630" txt_f="6632">/L</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="9850" xml_f="9910" txt_i="6633" txt_f="6687">Blasts &lt;5%, ringed sideroblasts &gt;15% of erythroblasts.</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9965" xml_f="9969" txt_i="6688" txt_f="6692">RAEB</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="10015" xml_f="10055" txt_i="6693" txt_f="6724">Blasts&gt;1%, &lt;5%, monocytes &lt;1×10</offsets><sup><offsets xml_i="10060" xml_f="10061" txt_i="6724" txt_f="6725">9</offsets></sup><offsets xml_i="10067" xml_f="10069" txt_i="6725" txt_f="6727">/L</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="10115" xml_f="10128" txt_i="6728" txt_f="6741">Blasts 5%–19%</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10183" xml_f="10189" txt_i="6742" txt_f="6748">RAEB-t</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="10235" xml_f="10264" txt_i="6749" txt_f="6775">Blasts &gt;5% or Auer rods or</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="10310" xml_f="10337" txt_i="6776" txt_f="6803">Blasts 20%–29% or Auer rods</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10392" xml_f="10423" txt_i="6804" txt_f="6835">Chronic myelomonocytic leukemia</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="10469" xml_f="10482" txt_i="6836" txt_f="6846">Blasts&lt;5%,</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="10528" xml_f="10585" txt_i="6847" txt_f="6904">Blasts up to 20%, promonocytes/monocytes often increased.</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><bold><offsets xml_i="10641" xml_f="10655" txt_i="6905" txt_f="6919">Abbreviations:</offsets></bold><offsets xml_i="10662" xml_f="10946" txt_i="6919" txt_f="7203"> BM, bone marrow; FAB, French, American, British classification of MDS; MDS, myelodysplastic syndromes; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; RARS, refractory anemia with ringed sideroblasts.</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label><offsets xml_i="11032" xml_f="11039" txt_i="7204" txt_f="7211">Table 2</offsets></label><caption><p><offsets xml_i="11059" xml_f="11088" txt_i="7211" txt_f="7240">The WHO Classification of MDS</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="11191" xml_f="11198" txt_i="7241" txt_f="7248">Disease</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="11244" xml_f="11269" txt_i="7248" txt_f="7273">Peripheral blood criteria</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="11315" xml_f="11326" txt_i="7273" txt_f="7284">BM Criteria</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="11396" xml_f="11398" txt_i="7284" txt_f="7286">RA</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="11444" xml_f="11469" txt_i="7287" txt_f="7312">Anemia, no or rare blasts</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="11515" xml_f="11584" txt_i="7313" txt_f="7376">Erythroid dysplasia alone, &lt;5% blasts, &lt;15% ringed sideroblasts</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="11639" xml_f="11643" txt_i="7377" txt_f="7381">RARS</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="11689" xml_f="11706" txt_i="7382" txt_f="7399">Anemia, no blasts</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="11752" xml_f="11821" txt_i="7400" txt_f="7463">Erythroid dysplasia alone, &lt;5% blasts, &gt;15% ringed sideroblasts</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="11876" xml_f="11924" txt_i="7464" txt_f="7512">Refractory cytopenia with multilineage dysplasia</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="11970" xml_f="12053" txt_i="7513" txt_f="7593">Cytopenias (bicytopenia or pancytopenia), no or rare blasts, no Auer rods, &lt;1×10</offsets><sup><offsets xml_i="12058" xml_f="12059" txt_i="7593" txt_f="7594">9</offsets></sup><offsets xml_i="12065" xml_f="12077" txt_i="7594" txt_f="7606">/L monocytes</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="12123" xml_f="12238" txt_i="7607" txt_f="7710">Dysplasia in &gt;10% of cells in &gt;2 myeloid cell lines, &lt;5% blasts, no Auer rods, &lt;15% ringed sideroblasts</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12293" xml_f="12365" txt_i="7711" txt_f="7783">Refractory cytopenia with multilineage dysplasia and ringed sideroblasts</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="12411" xml_f="12494" txt_i="7784" txt_f="7864">Cytopenias (bicytopenia or pancytopenia), no or rare blasts, no Auer rods, &lt;1×10</offsets><sup><offsets xml_i="12499" xml_f="12500" txt_i="7864" txt_f="7865">9</offsets></sup><offsets xml_i="12506" xml_f="12518" txt_i="7865" txt_f="7877">/L monocytes</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="12564" xml_f="12679" txt_i="7878" txt_f="7981">Dysplasia in &gt;10% of cells in &gt;2 myeloid cell lines, &lt;5% blasts, no Auer rods, &gt;15% ringed sideroblasts</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12734" xml_f="12745" txt_i="7982" txt_f="7993">RAEB type 1</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="12791" xml_f="12840" txt_i="7994" txt_f="8037">Cytopenias, &lt;5% blasts, no Auer rods, &lt;1×10</offsets><sup><offsets xml_i="12845" xml_f="12846" txt_i="8037" txt_f="8038">9</offsets></sup><offsets xml_i="12852" xml_f="12864" txt_i="8038" txt_f="8050">/L monocytes</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="12910" xml_f="12974" txt_i="8051" txt_f="8115">Unilineage or multilineage dysplasia, 5%–9% blasts, no Auer rods</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13029" xml_f="13040" txt_i="8116" txt_f="8127">RAEB type 2</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="13086" xml_f="13135" txt_i="8128" txt_f="8174">Cytopenias, 5%–19% blasts, no Auer rods, &lt;1×10</offsets><sup><offsets xml_i="13140" xml_f="13141" txt_i="8174" txt_f="8175">9</offsets></sup><offsets xml_i="13147" xml_f="13159" txt_i="8175" txt_f="8187">/L monocytes</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="13205" xml_f="13279" txt_i="8188" txt_f="8262">Unilineage or multilineage dysplasia, 10%–19% blasts, occasional Auer rods</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13334" xml_f="13350" txt_i="8263" txt_f="8279">MDS unclassified</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="13396" xml_f="13439" txt_i="8280" txt_f="8323">Cytopenias, no or rare blasts, no Auer rods</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="13485" xml_f="13568" txt_i="8324" txt_f="8404">Unilineage dysplasia in granulocytes or megakaryocytes, &lt;5% blasts, no Auer rods</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13623" xml_f="13665" txt_i="8405" txt_f="8447">MDS associated with isolated deletion (5q)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="13711" xml_f="13768" txt_i="8448" txt_f="8502">Anemia, &lt;5% blasts, platelet count normal to increased</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="13814" xml_f="13920" txt_i="8503" txt_f="8606">Normal-to-increased megakaryocytes with hypolobated nuclei, &lt;5% blasts, no Auer rods, isolated del (5q)</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><bold><offsets xml_i="13976" xml_f="13990" txt_i="8607" txt_f="8621">Abbreviations:</offsets></bold><offsets xml_i="13997" xml_f="14312" txt_i="8621" txt_f="8936"> BM, bone marrow; FAB, French, American, British classification of MDS; MDS, myelodysplastic syndromes; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; RARS, refractory anemia with ringed sideroblasts; WHO,World Health Organisation.</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label><offsets xml_i="14398" xml_f="14405" txt_i="8937" txt_f="8944">Table 3</offsets></label><caption><p><offsets xml_i="14425" xml_f="14456" txt_i="8944" txt_f="8975">The IPSS scoring system for MDS</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="14559" xml_f="14578" txt_i="8976" txt_f="8995">Prognostic variable</offsets></th><th colspan="5" align="left" rowspan="1"><offsets xml_i="14624" xml_f="14635" txt_i="8995" txt_f="9006">Score value</offsets></th></tr><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="14723" xml_f="14724" txt_i="9006" txt_f="9007">0</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="14770" xml_f="14773" txt_i="9007" txt_f="9010">0.5</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="14819" xml_f="14822" txt_i="9010" txt_f="9013">1.0</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="14868" xml_f="14871" txt_i="9013" txt_f="9016">1.5</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="14917" xml_f="14920" txt_i="9016" txt_f="9019">2.0</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14990" xml_f="15001" txt_i="9019" txt_f="9030">BM blasts %</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15047" xml_f="15052" txt_i="9031" txt_f="9033">&lt;5</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15098" xml_f="15102" txt_i="9034" txt_f="9038">5–10</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15148" xml_f="15149" txt_i="9039" txt_f="9040">–</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15195" xml_f="15200" txt_i="9041" txt_f="9046">11–20</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15246" xml_f="15251" txt_i="9047" txt_f="9052">21–30</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15306" xml_f="15315" txt_i="9053" txt_f="9062">Karyotype</offsets><xref ref-type="table-fn" rid="tf3-1"><offsets xml_i="15353" xml_f="15354" txt_i="9062" txt_f="9063">a</offsets></xref></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15407" xml_f="15411" txt_i="9064" txt_f="9068">Good</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15457" xml_f="15469" txt_i="9069" txt_f="9081">Intermediate</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15515" xml_f="15519" txt_i="9082" txt_f="9086">Poor</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15640" xml_f="15650" txt_i="9089" txt_f="9099">Cytopenias</offsets><xref ref-type="table-fn" rid="tf3-2"><offsets xml_i="15688" xml_f="15689" txt_i="9099" txt_f="9100">b</offsets></xref></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15742" xml_f="15748" txt_i="9101" txt_f="9107">0 or 1</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="15794" xml_f="15800" txt_i="9108" txt_f="9114">2 or 3</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><bold><offsets xml_i="15955" xml_f="15960" txt_i="9118" txt_f="9123">Note:</offsets></bold><offsets xml_i="15967" xml_f="16078" txt_i="9123" txt_f="9231"> Scores for risk groups are as follows: Low: 0, Intermediate-1: 0.5–1.0, Intermediate-2: 1.5–2.0, High &gt;2.5.</offsets></p></fn><fn id="tf3-1"><label><offsets xml_i="16109" xml_f="16110" txt_i="9232" txt_f="9233">a</offsets></label><p><offsets xml_i="16121" xml_f="16268" txt_i="9233" txt_f="9377">Karytotype: Good: normal, -Y, del(5q), del(20q); Poor: complex (&gt;3 abnormalities), or chromosome 7 anomalies; Intermediate: other abnormalities;</offsets></p></fn><fn id="tf3-2"><label><offsets xml_i="16299" xml_f="16300" txt_i="9378" txt_f="9379">b</offsets></label><p><offsets xml_i="16311" xml_f="16384" txt_i="9379" txt_f="9446">Cytopenias: defined as Hb&lt;10g/dl, Absolute neutrophil count &lt;1.5×10</offsets><sup><offsets xml_i="16389" xml_f="16390" txt_i="9446" txt_f="9447">9</offsets></sup><offsets xml_i="16396" xml_f="16428" txt_i="9447" txt_f="9476">/L and platelet count &lt;100×10</offsets><sup><offsets xml_i="16433" xml_f="16434" txt_i="9476" txt_f="9477">9</offsets></sup><offsets xml_i="16440" xml_f="16443" txt_i="9477" txt_f="9480">/L.</offsets></p></fn><fn><p><bold><offsets xml_i="16465" xml_f="16479" txt_i="9481" txt_f="9495">Abbreviations:</offsets></bold><offsets xml_i="16486" xml_f="16601" txt_i="9495" txt_f="9610"> BM, bone marrow; INT, intermediate; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndromes.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="16659" xml_f="16684" txt_i="9612" txt_f="9637">Epigenetic changes in MDS</offsets></title><p><offsets xml_i="16695" xml_f="16783" txt_i="9638" txt_f="9726">Epigenetics is the heritable change in gene expression without DNA sequence alteration (</offsets><xref ref-type="bibr" rid="b7"><offsets xml_i="16814" xml_f="16823" txt_i="9726" txt_f="9735">Bird 2002</offsets></xref><offsets xml_i="16830" xml_f="17045" txt_i="9735" txt_f="9950">). The primary epigenetic modifications are DNA methylation and histone modifications, both of which are potentially reversible. DNA methylation plays an important role in tissue and stage-specific gene regulation (</offsets><xref ref-type="bibr" rid="b34"><offsets xml_i="17077" xml_f="17099" txt_i="9950" txt_f="9972">Jaenisch and Bird 2003</offsets></xref><offsets xml_i="17106" xml_f="17132" txt_i="9972" txt_f="9998">) and increases with age (</offsets><xref ref-type="bibr" rid="b1"><offsets xml_i="17163" xml_f="17179" txt_i="9998" txt_f="10014">Ahuja et al 1998</offsets></xref><offsets xml_i="17186" xml_f="17550" txt_i="10014" txt_f="10378">). DNA methyltransferases (DNMT) mediate methylation by incorporating a methyl group into position 5 of the cytosine ring resulting in 5-methyl cytosine. This modification occurs most frequently in cytosines that precede guanosine in the DNA sequence called cytosine phosphodiester guanine (CpG) dinucleotides that occur in asymmetric clusters called CpG islands (</offsets><xref ref-type="bibr" rid="b22"><offsets xml_i="17582" xml_f="17614" txt_i="10378" txt_f="10410">Gardiner-Garden and Frommer 1987</offsets></xref><offsets xml_i="17621" xml_f="17623" txt_i="10410" txt_f="10412">; </offsets><xref ref-type="bibr" rid="b20"><offsets xml_i="17655" xml_f="17673" txt_i="10412" txt_f="10430">Frommer et al 1992</offsets></xref><offsets xml_i="17680" xml_f="17754" txt_i="10430" txt_f="10504">). These islands are often associated with the promoter regions of genes (</offsets><xref ref-type="bibr" rid="b16"><offsets xml_i="17786" xml_f="17804" txt_i="10504" txt_f="10522">Delgado et al 1998</offsets></xref><offsets xml_i="17811" xml_f="17897" txt_i="10522" txt_f="10608">) and are usually unmethylated irrespective of whether the gene is being transcribed (</offsets><xref ref-type="bibr" rid="b8"><offsets xml_i="17928" xml_f="17943" txt_i="10608" txt_f="10623">Bird et al 1979</offsets></xref><offsets xml_i="17950" xml_f="18086" txt_i="10623" txt_f="10759">). However aberrant methylation of such promoter regions can occur in disease, particularly cancers and correlates with gene silencing (</offsets><xref ref-type="bibr" rid="b3"><offsets xml_i="18117" xml_f="18137" txt_i="10759" txt_f="10779">Antequera et al 1990</offsets></xref><offsets xml_i="18144" xml_f="18297" txt_i="10779" txt_f="10932">). Maintenance methylation is carried out by DNMT1 whereas de novo methylation is mediated by DNMT 3a and 3b although these functions are not exclusive (</offsets><xref ref-type="bibr" rid="b51"><offsets xml_i="18329" xml_f="18345" txt_i="10932" txt_f="10948">Okano et al 1999</offsets></xref><offsets xml_i="18352" xml_f="18645" txt_i="10948" txt_f="11241">). Cancer is characterized by global DNA hypomethylation and regional promoter hypermethylation of genes. This hypermethylation occurs in a non-random, tumor specific manner and hypermethylation of tumor suppressor genes may act as the second inactivating hit invoked in Knudson’s hypothesis (</offsets><xref ref-type="bibr" rid="b39"><offsets xml_i="18677" xml_f="18693" txt_i="11241" txt_f="11257">Jones et al 1998</offsets></xref><offsets xml_i="18700" xml_f="18742" txt_i="11257" txt_f="11299">). Several tumor suppressor genes such as </offsets><italic><offsets xml_i="18750" xml_f="18753" txt_i="11299" txt_f="11302">VHL</offsets></italic><offsets xml_i="18762" xml_f="18780" txt_i="11302" txt_f="11320"> in renal cancer (</offsets><xref ref-type="bibr" rid="b31"><offsets xml_i="18812" xml_f="18829" txt_i="11320" txt_f="11337">Herman et al 1994</offsets></xref><offsets xml_i="18836" xml_f="18842" txt_i="11337" txt_f="11343">), p16</offsets><sup><offsets xml_i="18847" xml_f="18852" txt_i="11343" txt_f="11348">INK4A</offsets></sup><offsets xml_i="18858" xml_f="18890" txt_i="11348" txt_f="11380"> in solid tumors and lymphomas (</offsets><xref ref-type="bibr" rid="b19"><offsets xml_i="18922" xml_f="18941" txt_i="11380" txt_f="11399">Esteller et al 2001</offsets></xref><offsets xml_i="18948" xml_f="18950" txt_i="11399" txt_f="11401">; </offsets><xref ref-type="bibr" rid="b21"><offsets xml_i="18982" xml_f="18999" txt_i="11401" txt_f="11418">Garcia et al 2002</offsets></xref><offsets xml_i="19006" xml_f="19073" txt_i="11418" txt_f="11485">), E-Cadherin in breast, thyroid, gastric, and colorectal cancers (</offsets><xref ref-type="bibr" rid="b67"><offsets xml_i="19105" xml_f="19117" txt_i="11485" txt_f="11497">Wheeler 2005</offsets></xref><offsets xml_i="19124" xml_f="19201" txt_i="11497" txt_f="11574">) are inactivated by promoter hypermethylation. Promoter hypermethylation of </offsets><italic><offsets xml_i="19209" xml_f="19215" txt_i="11574" txt_f="11580">CDKN2B</offsets></italic><offsets xml_i="19224" xml_f="19238" txt_i="11580" txt_f="11594"> (encoding p15</offsets><sup><offsets xml_i="19243" xml_f="19248" txt_i="11594" txt_f="11599">INK4b</offsets></sup><offsets xml_i="19254" xml_f="19323" txt_i="11599" txt_f="11668">) has been shown to be restricted to the hematological malignancies (</offsets><xref ref-type="bibr" rid="b19"><offsets xml_i="19355" xml_f="19374" txt_i="11668" txt_f="11687">Esteller et al 2001</offsets></xref><offsets xml_i="19381" xml_f="19383" txt_i="11687" txt_f="11689">).</offsets></p></sec><sec><title><offsets xml_i="19405" xml_f="19430" txt_i="11691" txt_f="11716">Epigenetic studies in MDS</offsets></title><p><offsets xml_i="19441" xml_f="19572" txt_i="11717" txt_f="11848">In MDS epigenetic studies to date have focused on the methylation of cell cycle regulatory genes such as the tumor suppressor gene </offsets><italic><offsets xml_i="19580" xml_f="19586" txt_i="11848" txt_f="11854">CDKN2B</offsets></italic><offsets xml_i="19595" xml_f="19650" txt_i="11854" txt_f="11909"> that encodes the cyclin dependent kinase inhibitor p15</offsets><sup><offsets xml_i="19655" xml_f="19660" txt_i="11909" txt_f="11914">INK4b</offsets></sup><offsets xml_i="19666" xml_f="19671" txt_i="11914" txt_f="11919">. p15</offsets><sup><offsets xml_i="19676" xml_f="19681" txt_i="11919" txt_f="11924">INK4b</offsets></sup><offsets xml_i="19687" xml_f="19837" txt_i="11924" txt_f="12074"> inhibits quiescent cells from entering the cell cycle and is important in preventing the uncontrolled proliferation of human hemopoietic stem cells (</offsets><xref ref-type="bibr" rid="b15"><offsets xml_i="19869" xml_f="19883" txt_i="12074" txt_f="12088">Dao et al 1998</offsets></xref><offsets xml_i="19890" xml_f="19909" txt_i="12088" txt_f="12107">). Induction of p15</offsets><sup><offsets xml_i="19914" xml_f="19919" txt_i="12107" txt_f="12112">INK4b</offsets></sup><offsets xml_i="19925" xml_f="20044" txt_i="12112" txt_f="12231"> by cytokines leads to myeloid progenitors being retained in G0 and differentiating into granulocytes and macrophages (</offsets><xref ref-type="bibr" rid="b2"><offsets xml_i="20075" xml_f="20095" txt_i="12231" txt_f="12251">Amanullah et al 2000</offsets></xref><offsets xml_i="20102" xml_f="20104" txt_i="12251" txt_f="12253">; </offsets><xref ref-type="bibr" rid="b60"><offsets xml_i="20136" xml_f="20154" txt_i="12253" txt_f="12271">Teofili et al 2000</offsets></xref><offsets xml_i="20161" xml_f="20199" txt_i="12271" txt_f="12309">). It is postulated that silencing of </offsets><italic><offsets xml_i="20207" xml_f="20213" txt_i="12309" txt_f="12315">CDKN2B</offsets></italic><offsets xml_i="20222" xml_f="20419" txt_i="12315" txt_f="12512"> by promoter methylation in MDS leads to sustained progenitor proliferation without differentiation resulting in peripheral cytopenias and an excess of blasts, which are a hallmark of the disease (</offsets><xref ref-type="bibr" rid="b18"><offsets xml_i="20451" xml_f="20463" txt_i="12512" txt_f="12524">Drexler 1998</offsets></xref><offsets xml_i="20470" xml_f="20472" txt_i="12524" txt_f="12526">; </offsets><xref ref-type="bibr" rid="b9"><offsets xml_i="20503" xml_f="20521" txt_i="12526" txt_f="12544">Cameron et al 1999</offsets></xref><offsets xml_i="20528" xml_f="20530" txt_i="12544" txt_f="12546">).</offsets></p><p><offsets xml_i="20537" xml_f="20619" txt_i="12547" txt_f="12629">Hypermethylation of other genes such as the calcitonin gene occurs in 65% of MDS (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="20651" xml_f="20671" txt_i="12629" txt_f="12649">Dhodapkar et al 1995</offsets></xref><offsets xml_i="20678" xml_f="20701" txt_i="12649" txt_f="12672">). Other genes such as </offsets><italic><offsets xml_i="20709" xml_f="20712" txt_i="12672" txt_f="12675">HIC</offsets></italic><offsets xml_i="20721" xml_f="20751" txt_i="12675" txt_f="12705"> (Hypermethylated in cancer), </offsets><italic><offsets xml_i="20759" xml_f="20769" txt_i="12705" txt_f="12715">E cadherin</offsets></italic><offsets xml_i="20778" xml_f="20780" txt_i="12715" txt_f="12717"> (</offsets><xref ref-type="bibr" rid="b13"><offsets xml_i="20812" xml_f="20827" txt_i="12717" txt_f="12732">Corn et al 2000</offsets></xref><offsets xml_i="20834" xml_f="20840" txt_i="12732" txt_f="12738">) and </offsets><italic><offsets xml_i="20848" xml_f="20850" txt_i="12738" txt_f="12740">ER</offsets></italic><offsets xml_i="20859" xml_f="20917" txt_i="12740" txt_f="12798"> (Estrogen Receptor) are also hypermethylated in MDS–AML. </offsets><italic><offsets xml_i="20925" xml_f="20929" txt_i="12798" txt_f="12802">SOCS</offsets></italic><offsets xml_i="20938" xml_f="21202" txt_i="12802" txt_f="13066"> (Suppressor of Cytokines) methylation occurs in 31% of patients with MDS suggesting that activation of the Janus kinase – Signal transducer activation of transcription (JAK-STAT) pathway plays an important role in the progression of the disease in some patients (</offsets><xref ref-type="bibr" rid="b35"><offsets xml_i="21234" xml_f="21250" txt_i="13066" txt_f="13082">Johan et al 2004</offsets></xref><offsets xml_i="21257" xml_f="21259" txt_i="13082" txt_f="13084">).</offsets></p><p><offsets xml_i="21266" xml_f="21643" txt_i="13085" txt_f="13462">In AML numerous genes are concurrently hypermethylated suggesting that normal DNA methylation mechanisms are disrupted. Methylation profiling of the calcitonin, estrogen receptor, E-Cadherin, p15, p16, Rb, GST-Pi, and HIC1 gene promoters in AML showed that 95% had an abnormal methylation pattern in at least one gene whereas 75% had abnormal methylation of two or more genes (</offsets><xref ref-type="bibr" rid="b44"><offsets xml_i="21675" xml_f="21691" txt_i="13462" txt_f="13478">Melki et al 1999</offsets></xref><offsets xml_i="21698" xml_f="22019" txt_i="13478" txt_f="13799">). In AML 160 of 261 (61%) patients (age less than 65) had estrogen receptor methylation (ERM). ERM decreased with increasing age (p=0.0001) and was significantly lower in patients with myelomonocytic and monocytic AML (FAB M4/M5) (p=0.0019). ERM positive patients had a significantly better overall survival (p=0.0044) (</offsets><xref ref-type="bibr" rid="b42"><offsets xml_i="22051" xml_f="22064" txt_i="13799" txt_f="13812">Li et al 1999</offsets></xref><offsets xml_i="22071" xml_f="22174" txt_i="13812" txt_f="13915">). Furthermore, methylation profiling of a subset of the cases studied for ERM (36 cases of AML) found </offsets><italic><offsets xml_i="22182" xml_f="22184" txt_i="13915" txt_f="13917">ER</offsets></italic><offsets xml_i="22193" xml_f="22241" txt_i="13917" txt_f="13965"> to be frequently hypermethylated (47%) as were </offsets><italic><offsets xml_i="22249" xml_f="22254" txt_i="13965" txt_f="13970">MYOD1</offsets></italic><offsets xml_i="22263" xml_f="22265" txt_i="13970" txt_f="13972">, </offsets><italic><offsets xml_i="22273" xml_f="22278" txt_i="13972" txt_f="13977">PITX2</offsets></italic><offsets xml_i="22287" xml_f="22289" txt_i="13977" txt_f="13979">, </offsets><italic><offsets xml_i="22297" xml_f="22302" txt_i="13979" txt_f="13984">GPR37</offsets></italic><offsets xml_i="22311" xml_f="22317" txt_i="13984" txt_f="13990">, and </offsets><italic><offsets xml_i="22325" xml_f="22329" txt_i="13990" txt_f="13994">SDC4</offsets></italic><offsets xml_i="22338" xml_f="22489" txt_i="13994" txt_f="14145">. Importantly the methylation density of each of the CpG islands correlated with ERM density suggesting the presence of a methylator phenotype in AML (</offsets><xref ref-type="bibr" rid="b63"><offsets xml_i="22521" xml_f="22538" txt_i="14145" txt_f="14162">Toyota et al 2001</offsets></xref><offsets xml_i="22545" xml_f="22633" txt_i="14162" txt_f="14250">) and a means of identifying patients in whom demethylating therapy may be appropriate. </offsets><xref ref-type="bibr" rid="b57"><offsets xml_i="22665" xml_f="22682" txt_i="14250" txt_f="14267">Rush et al (2001)</offsets></xref><offsets xml_i="22689" xml_f="22907" txt_i="14267" txt_f="14485"> further identified a predisposition for chromosome 11 methylation, in patients with de-novo AML. Several fold increases in DNMT1, DNMT3a, and DNMT3b that correlated with aberrant p15 methylation also occurred in AML (</offsets><xref ref-type="bibr" rid="b45"><offsets xml_i="22939" xml_f="22956" txt_i="14485" txt_f="14502">Mizuno et al 2001</offsets></xref><offsets xml_i="22963" xml_f="22965" txt_i="14502" txt_f="14504">).</offsets></p><p><offsets xml_i="22972" xml_f="23164" txt_i="14505" txt_f="14697">However, the precise relationship between hypermethylation of the promoters of these genes and their contribution to the pathogenesis and progression of MDS remains unclear except perhaps for </offsets><italic><offsets xml_i="23172" xml_f="23178" txt_i="14697" txt_f="14703">CDKN2B</offsets></italic><offsets xml_i="23187" xml_f="23188" txt_i="14703" txt_f="14704">.</offsets></p><p><offsets xml_i="23195" xml_f="23318" txt_i="14705" txt_f="14828">Progression to AML occurs frequently in patients with RAEB (28%) and RAEBt (45%) but less often in RA (10%) and RARS (8%) (</offsets><xref ref-type="bibr" rid="b23"><offsets xml_i="23350" xml_f="23368" txt_i="14828" txt_f="14846">Germing et al 2000</offsets></xref><offsets xml_i="23375" xml_f="23583" txt_i="14846" txt_f="15054">). The IPSS score identifies chromosome abnormalities (chromosome 7 and complex cytogenetics) and increasing blast percentage as being important predictors of leukemic transformation. Hypermethylation of the </offsets><italic><offsets xml_i="23591" xml_f="23597" txt_i="15054" txt_f="15060">CDKN2B</offsets></italic><offsets xml_i="23606" xml_f="23655" txt_i="15060" txt_f="15109"> promoter appears important in MDS evolution. p15</offsets><sup><offsets xml_i="23660" xml_f="23665" txt_i="15109" txt_f="15114">INK4b</offsets></sup><offsets xml_i="23671" xml_f="23765" txt_i="15114" txt_f="15208"> is upregulated during in vitro granulocytic and megakaryocytic differentiation of normal CD34</offsets><sup><offsets xml_i="23770" xml_f="23771" txt_i="15208" txt_f="15209">+</offsets></sup><offsets xml_i="23777" xml_f="23803" txt_i="15209" txt_f="15235"> hemopoietic progenitors (</offsets><xref ref-type="bibr" rid="b59"><offsets xml_i="23835" xml_f="23853" txt_i="15235" txt_f="15253">Teofili et al 2001</offsets></xref><offsets xml_i="23860" xml_f="23889" txt_i="15253" txt_f="15282">). Deletions or mutations of </offsets><italic><offsets xml_i="23897" xml_f="23903" txt_i="15282" txt_f="15288">CDKN2B</offsets></italic><offsets xml_i="23912" xml_f="23934" txt_i="15288" txt_f="15310"> are uncommon in MDS (</offsets><xref ref-type="bibr" rid="b50"><offsets xml_i="23966" xml_f="23985" txt_i="15310" txt_f="15329">Nakamaki et al 1997</offsets></xref><offsets xml_i="23992" xml_f="24012" txt_i="15329" txt_f="15349">). The frequency of </offsets><italic><offsets xml_i="24020" xml_f="24026" txt_i="15349" txt_f="15355">CDKN2B</offsets></italic><offsets xml_i="24035" xml_f="24203" txt_i="15355" txt_f="15523"> methylation is low (23%) in early MDS however its presence at diagnosis is predictive of progressive disease and its acquisition also accompanies disease progression (</offsets><xref ref-type="bibr" rid="b62"><offsets xml_i="24235" xml_f="24250" txt_i="15523" txt_f="15538">Tien et al 2001</offsets></xref><offsets xml_i="24257" xml_f="24272" txt_i="15538" txt_f="15553">). Furthermore </offsets><italic><offsets xml_i="24280" xml_f="24286" txt_i="15553" txt_f="15559">CDKN2B</offsets></italic><offsets xml_i="24295" xml_f="24398" txt_i="15559" txt_f="15662"> hypermethylation occurs frequently in RAEB, RAEBt particularly in patients with more than 10% blasts (</offsets><xref ref-type="bibr" rid="b53"><offsets xml_i="24430" xml_f="24448" txt_i="15662" txt_f="15680">Quesnel et al 1998</offsets></xref><offsets xml_i="24455" xml_f="24457" txt_i="15680" txt_f="15682">; </offsets><xref ref-type="bibr" rid="b64"><offsets xml_i="24489" xml_f="24506" txt_i="15682" txt_f="15699">Uchida et al 1998</offsets></xref><offsets xml_i="24513" xml_f="24533" txt_i="15699" txt_f="15719">). The incidence of </offsets><italic><offsets xml_i="24541" xml_f="24547" txt_i="15719" txt_f="15725">CDKN2B</offsets></italic><offsets xml_i="24556" xml_f="24619" txt_i="15725" txt_f="15788"> methylation is 58% in chronic myelomonocytic leukemia (CMML) (</offsets><xref ref-type="bibr" rid="b61"><offsets xml_i="24651" xml_f="24669" txt_i="15788" txt_f="15806">Tessema et al 2003</offsets></xref><offsets xml_i="24676" xml_f="24702" txt_i="15806" txt_f="15832">) and 60%–75% in MDS–AML (</offsets><xref ref-type="bibr" rid="b62"><offsets xml_i="24734" xml_f="24749" txt_i="15832" txt_f="15847">Tien et al 2001</offsets></xref><offsets xml_i="24756" xml_f="24914" txt_i="15847" txt_f="16005">). Therapy related MDS (t-MDS, MDS occurring in individuals previously treated with either cytotoxic chemotherapy and or radiotherapy) is also accompanied by </offsets><italic><offsets xml_i="24922" xml_f="24928" txt_i="16005" txt_f="16011">CDKN2B</offsets></italic><offsets xml_i="24937" xml_f="25111" txt_i="16011" txt_f="16185"> promoter methylation and CpG methylation density has both been shown to increase significantly with advanced MDS subtypes (p=0.004 and p=0.0002) and deletion or loss of 7q (</offsets><xref ref-type="bibr" rid="b11"><offsets xml_i="25143" xml_f="25166" txt_i="16185" txt_f="16208">Christiansen et al 2003</offsets></xref><offsets xml_i="25173" xml_f="25181" txt_i="16208" txt_f="16216">). Thus </offsets><italic><offsets xml_i="25189" xml_f="25195" txt_i="16216" txt_f="16222">CDKN2B</offsets></italic><offsets xml_i="25204" xml_f="25286" txt_i="16222" txt_f="16304"> appears important in disease progression and in the development of high risk MDS.</offsets></p></sec><sec><title><offsets xml_i="25308" xml_f="25328" txt_i="16306" txt_f="16326">5-Azacytidine in MDS</offsets></title><sec><title><offsets xml_i="25348" xml_f="25369" txt_i="16327" txt_f="16348">Rationale for its use</offsets></title><p><offsets xml_i="25380" xml_f="25465" txt_i="16349" txt_f="16434">Azacytidine is a DNMT inhibitor that has in vitro and in vivo demethylating effects (</offsets><xref ref-type="bibr" rid="b38"><offsets xml_i="25497" xml_f="25513" txt_i="16434" txt_f="16450">Jones et al 1983</offsets></xref><offsets xml_i="25520" xml_f="25544" txt_i="16450" txt_f="16474">). Since methylation of </offsets><italic><offsets xml_i="25552" xml_f="25558" txt_i="16474" txt_f="16480">CDKN2B</offsets></italic><offsets xml_i="25567" xml_f="25814" txt_i="16480" txt_f="16727"> occurs at a high frequency in MDS and is acquired during disease progression, reactivation by demethylation may halt disease progression. At high doses Azacytidine is cytotoxic whereas at lower doses it induces differentiation and demethylation (</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="25846" xml_f="25860" txt_i="16727" txt_f="16741">Christman 2002</offsets></xref><offsets xml_i="25867" xml_f="26081" txt_i="16741" txt_f="16955">). Clinical evidence for its efficacy in acute myeloid leukemia comes from 8 trials involving approximately 200 patients, treated with cytotoxic doses of Azacytidine (intravenously at doses ranging from 60–750 mg/m</offsets><sup><offsets xml_i="26086" xml_f="26087" txt_i="16955" txt_f="16956">2</offsets></sup><offsets xml_i="26093" xml_f="26483" txt_i="16956" txt_f="17346"> once daily or as a repeated dose for up to 10 days) resulting in an overall response rate of 36% (20% complete remission [CR] and 16% partial response [PR]). These results were considerably better than the results achieved in patients with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and solid tumors demonstrating the anti-leukemic activity of Azacytidine in AML (</offsets><xref ref-type="bibr" rid="b24"><offsets xml_i="26515" xml_f="26532" txt_i="17346" txt_f="17363">Glover et al 1987</offsets></xref><offsets xml_i="26539" xml_f="26541" txt_i="17363" txt_f="17365">).</offsets></p></sec><sec><title><offsets xml_i="26563" xml_f="26619" txt_i="17367" txt_f="17423">Chemical structure and pharmacokinetics of 5-Azacytidine</offsets></title><p><offsets xml_i="26630" xml_f="27012" txt_i="17424" txt_f="17806">5-Azacytidine (Vidaza®) is a chemically synthesized nucleoside analogue that was manufactured in the 1960s. Its role as a DNMT inhibitor (MTI) that can potentially reverse pathogenic epigenetic events such as methylation of genes has led to renewed interest and enthusiasm in the drug. 5 Azacytidine is a pyrimidine ring analogue in which the ring carbon 5 is replaced by nitrogen (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="27044" xml_f="27052" txt_i="17806" txt_f="17814">Figure 1</offsets></xref><offsets xml_i="27059" xml_f="27104" txt_i="17814" txt_f="17859">). It is incorporated into both RNA and DNA (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="27136" xml_f="27144" txt_i="17859" txt_f="17867">Figure 2</offsets></xref><offsets xml_i="27151" xml_f="27224" txt_i="17867" txt_f="17940">). In DNA it binds DNMT, irreversibly leading to loss of their activity (</offsets><xref ref-type="bibr" rid="b14"><offsets xml_i="27256" xml_f="27274" txt_i="17940" txt_f="17958">Creusot et al 1982</offsets></xref><offsets xml_i="27281" xml_f="27283" txt_i="17958" txt_f="17960">; </offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="27315" xml_f="27329" txt_i="17960" txt_f="17974">Christman 2002</offsets></xref><offsets xml_i="27336" xml_f="27436" txt_i="17974" txt_f="18074">). Additionally DNA cannot be methylated resulting in almost complete demethylation of genomic DNA (</offsets><xref ref-type="bibr" rid="b37"><offsets xml_i="27468" xml_f="27489" txt_i="18074" txt_f="18095">Jones and Taylor 1981</offsets></xref><offsets xml_i="27496" xml_f="27577" txt_i="18095" txt_f="18176">). De-novo methylation is therefore inhibited, resulting in DNA hypomethylation (</offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="27609" xml_f="27617" txt_i="18176" txt_f="18184">Figure 3</offsets></xref><offsets xml_i="27624" xml_f="27690" txt_i="18184" txt_f="18250">). The DNMT and Azacytidine adducts are also toxic and mutagenic (</offsets><xref ref-type="bibr" rid="b6"><offsets xml_i="27721" xml_f="27745" txt_i="18250" txt_f="18274">Bhagwat and Roberts 1987</offsets></xref><offsets xml_i="27752" xml_f="27930" txt_i="18274" txt_f="18452">). In vitro Azacytidine leads to decondensation of chromatin, chromosomal instability, and extends the replication time of normally late replicating heterochromatin (reviewed in </offsets><xref ref-type="bibr" rid="b29"><offsets xml_i="27962" xml_f="27971" txt_i="18452" txt_f="18461">Haaf 1995</offsets></xref><offsets xml_i="27978" xml_f="27980" txt_i="18461" txt_f="18463">).</offsets></p><fig id="fig1" position="float"><label><offsets xml_i="28023" xml_f="28031" txt_i="18464" txt_f="18472">Figure 1</offsets></label><caption><p><offsets xml_i="28051" xml_f="28255" txt_i="18472" txt_f="18676">The ring structure of 5 Azacytidine and 5 Aza-2-deoxycytidine showing substitution of N at position 5. Azacytidine is attached to a ribose sugar whereas 5 Aza-2-deoxycytidine is attached to a deoxyribose.</offsets></p></caption><graphic xlink:href="tcrm0204-377-01"></graphic></fig><fig id="fig2" position="float"><label><offsets xml_i="28362" xml_f="28370" txt_i="18677" txt_f="18685">Figure 2</offsets></label><caption><p><offsets xml_i="28390" xml_f="28491" txt_i="18685" txt_f="18786">Incorporation of Azacytidine into RNA and its metabolite 5 Aza 2 deoxycytidine (Decitabine) into DNA.</offsets></p><p><bold><offsets xml_i="28504" xml_f="28518" txt_i="18787" txt_f="18801">Abbreviations:</offsets></bold><offsets xml_i="28525" xml_f="28796" txt_i="18801" txt_f="19072"> CMP,cytidine monophosphate ;CDP, Cytidine diphosphate, CTP, Cytidine triphosphate, CR, azacytidine; dCR, decitabine; dCMP, deoxyctidine monophosphate; dCDP, deoxycytidine diphosphate ; dCTP,deoxy cytidine triphosphate ; DNA, deoxyribonucleic acid; RNA, ribonucleic acid.</offsets></p></caption><graphic xlink:href="tcrm0204-377-02"></graphic></fig><fig id="fig3" position="float"><label><offsets xml_i="28903" xml_f="28911" txt_i="19073" txt_f="19081">Figure 3</offsets></label><caption><p><offsets xml_i="28931" xml_f="29320" txt_i="19081" txt_f="19470">Demethylation by MTI’s. Hemimethylated DNA (mC) attracts DNMT that mediate copying of methylation onto the unmethylated sister strand once DNA replicates.When Azacytidine is incorporated into DNA it binds DNMT irreversibly resulting in its degradation.Thus replication of methylation is prevented resulting in passive demethylation of DNA when DNA replicates. Adapted with permission from </offsets><xref ref-type="bibr" rid="b58"><offsets xml_i="29352" xml_f="29402" txt_i="19470" txt_f="19520">Silverman LR, Demakos EP, Peterson BL, et al. 2002</offsets></xref><offsets xml_i="29409" xml_f="29545" txt_i="19520" txt_f="19656">. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. </offsets><italic><offsets xml_i="29553" xml_f="29565" txt_i="19656" txt_f="19668">J Clin Oncol</offsets></italic><offsets xml_i="29574" xml_f="29587" txt_i="19668" txt_f="19681">, 20:2429–40.</offsets></p><p><bold><offsets xml_i="29600" xml_f="29614" txt_i="19682" txt_f="19696">Abbreviations:</offsets></bold><offsets xml_i="29621" xml_f="29800" txt_i="19696" txt_f="19875"> A, adenosine; aC, azacytidine, ; DNA, deoxyribonucleic acid; DNMT, DNA methyl transferase; G, guanosine ; mC, methylated cytosine; MTI, methyltransferase inhibitors;T, thymidine.</offsets></p></caption><graphic xlink:href="tcrm0204-377-03"></graphic></fig><p><offsets xml_i="29871" xml_f="30268" txt_i="19876" txt_f="20273">Azacytidine is chemically unstable due to the chemical substitution of nitrogen at position 5. This resulted in it being manufactured as a lyophilized powder. Each single use vial contains 100 mg of Azacytidine and 100 mg of Mannitol that is reconstituted to 25 mg/ml in sterile water. It is stable refrigerated for up to 8 hours but otherwise has to be administered within an hour of preparation.</offsets></p><p><offsets xml_i="30275" xml_f="30545" txt_i="20274" txt_f="20544">Azacytidine may be used intravenously or subcutaneously with a similar bioavailability. It is rapidly absorbed subcutaneously achieving a maximal concentration within half an hour, and the concentration achieved is proportional to the dose administered (range 10–75 mg/m</offsets><sup><offsets xml_i="30550" xml_f="30551" txt_i="20544" txt_f="20545">2</offsets></sup><offsets xml_i="30557" xml_f="30650" txt_i="20545" txt_f="20638">). It has a half-life of 1.5–2.3 hours and is undetectable 8 hours following administration (</offsets><xref ref-type="bibr" rid="b56"><offsets xml_i="30682" xml_f="30698" txt_i="20638" txt_f="20654">Rudek et al 2005</offsets></xref><offsets xml_i="30705" xml_f="30707" txt_i="20654" txt_f="20656">).</offsets></p><p><offsets xml_i="30714" xml_f="30963" txt_i="20657" txt_f="20906">Azacytidine is phosphorylated by uridine-cytidine kinase and is incorporated as a monophosphate into newly synthesized RNA. It is metabolized by cytidine deaminase resulting in the production of 5 azauridine that is mainly eliminated by the kidneys.</offsets></p></sec><sec><title><offsets xml_i="30985" xml_f="31017" txt_i="20908" txt_f="20940">Clinical trials with Azacytidine</offsets></title><p><offsets xml_i="31028" xml_f="31247" txt_i="20941" txt_f="21160">Three successive Cancer and Leukemia Group B (CALGB) studies culminating in the phase III randomized controlled trial comparing 5 Azacytidine with best supportive care have demonstrated its effectiveness (summarized in </offsets><xref ref-type="table" rid="tbl4"><offsets xml_i="31281" xml_f="31288" txt_i="21160" txt_f="21167">Table 4</offsets></xref><offsets xml_i="31295" xml_f="31354" txt_i="21167" txt_f="21226">). The dose of Azacytidine in all these studies was 75 mg/m</offsets><sup><offsets xml_i="31359" xml_f="31360" txt_i="21226" txt_f="21227">2</offsets></sup><offsets xml_i="31366" xml_f="31789" txt_i="21227" txt_f="21650">. In the first study CALGB 8421 the drug was administered intravenously initially and later converted to subcutaneous use, which was continued in CALGB 8921 and 9221. CALGB 8421 was an uncontrolled phase 2 study that enrolled patients with RAEB, RAEBt (excluded CMML) who had not received prior radiotherapy or chemotherapy although prior treatment with low dose cytarabine was permitted. Patients were treated with 75 mg/m</offsets><sup><offsets xml_i="31794" xml_f="31795" txt_i="21650" txt_f="21651">2</offsets></sup><offsets xml_i="31801" xml_f="31874" txt_i="21651" txt_f="21724"> intravenous (IV) continuous infusion and a dose escalation up to 150mg/m</offsets><sup><offsets xml_i="31879" xml_f="31880" txt_i="21724" txt_f="21725">2</offsets></sup></p><table-wrap id="tbl4" position="float"><label><offsets xml_i="31936" xml_f="31943" txt_i="21726" txt_f="21733">Table 4</offsets></label><caption><p><offsets xml_i="31963" xml_f="31987" txt_i="21733" txt_f="21757">CALGB Azacytidine trials</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="32123" xml_f="32141" txt_i="21758" txt_f="21776">Trial 8421 Phase I</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="32187" xml_f="32206" txt_i="21776" txt_f="21795">Trial 8921 Phase II</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="32252" xml_f="32266" txt_i="21795" txt_f="21809">Trial 9221	RCT</offsets></th><th rowspan="1" colspan="1"></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32402" xml_f="32413" txt_i="21810" txt_f="21821">Intravenous</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32459" xml_f="32471" txt_i="21822" txt_f="21834">Subcutaneous</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32517" xml_f="32532" txt_i="21835" txt_f="21850">Supportive care</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32578" xml_f="32589" txt_i="21851" txt_f="21862">Azacytidine</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32644" xml_f="32661" txt_i="21863" txt_f="21880">Patient evaluated</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32707" xml_f="32709" txt_i="21881" txt_f="21883">43</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32755" xml_f="32757" txt_i="21884" txt_f="21886">68</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32803" xml_f="32805" txt_i="21887" txt_f="21889">92</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32851" xml_f="32853" txt_i="21890" txt_f="21892">99</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32908" xml_f="32910" txt_i="21893" txt_f="21895">CR</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="32956" xml_f="32963" txt_i="21896" txt_f="21903">5 (12%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33009" xml_f="33016" txt_i="21904" txt_f="21911">8 (12%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33062" xml_f="33068" txt_i="21912" txt_f="21918">0 (0%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33114" xml_f="33119" txt_i="21919" txt_f="21924">7(7%)</offsets><xref ref-type="table-fn" rid="tf4-1"><offsets xml_i="33157" xml_f="33158" txt_i="21924" txt_f="21925">*</offsets></xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="33220" xml_f="33222" txt_i="21926" txt_f="21928">PR</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33268" xml_f="33276" txt_i="21929" txt_f="21937">11 (25%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33322" xml_f="33330" txt_i="21938" txt_f="21946">10 (15%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33376" xml_f="33382" txt_i="21947" txt_f="21953">0 (0%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33428" xml_f="33436" txt_i="21954" txt_f="21962">16 (16%)</offsets><xref ref-type="table-fn" rid="tf4-2"><offsets xml_i="33474" xml_f="33475" txt_i="21962" txt_f="21963">+</offsets></xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="33537" xml_f="33545" txt_i="21964" txt_f="21972">Improved</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33591" xml_f="33598" txt_i="21973" txt_f="21980">5 (12%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33644" xml_f="33652" txt_i="21981" txt_f="21989">18 (27%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33698" xml_f="33704" txt_i="21990" txt_f="21996">5 (5%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33750" xml_f="33758" txt_i="21997" txt_f="22005">37 (37%)</offsets><xref ref-type="table-fn" rid="tf4-2"><offsets xml_i="33796" xml_f="33797" txt_i="22005" txt_f="22006">+</offsets></xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="33859" xml_f="33873" txt_i="22007" txt_f="22021">Total response</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33919" xml_f="33927" txt_i="22022" txt_f="22030">21 (49%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="33973" xml_f="33981" txt_i="22031" txt_f="22039">36 (53%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="34027" xml_f="34033" txt_i="22040" txt_f="22046">5 (5%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="34079" xml_f="34087" txt_i="22047" txt_f="22055">60 (60%)</offsets><xref ref-type="table-fn" rid="tf4-2"><offsets xml_i="34125" xml_f="34126" txt_i="22055" txt_f="22056">+</offsets></xref></td></tr></tbody></table><table-wrap-foot><fn id="tf4-1"><label><offsets xml_i="34198" xml_f="34199" txt_i="22057" txt_f="22058">*</offsets></label><p><bold><offsets xml_i="34216" xml_f="34221" txt_i="22058" txt_f="22063">Note:</offsets></bold><offsets xml_i="34228" xml_f="34236" txt_i="22063" txt_f="22071"> p=0.01,</offsets></p></fn><fn id="tf4-2"><label><offsets xml_i="34267" xml_f="34268" txt_i="22072" txt_f="22073">+</offsets></label><p><offsets xml_i="34279" xml_f="34290" txt_i="22073" txt_f="22081">p&lt;0.0001</offsets></p></fn><fn><p><bold><offsets xml_i="34312" xml_f="34326" txt_i="22082" txt_f="22096">Abbreviations:</offsets></bold><offsets xml_i="34333" xml_f="34448" txt_i="22096" txt_f="22211"> CALGB, Cancer And Leukemia Group B; CR, complete response; PR, partial response, RCT, randomized controlled trial.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="34491" xml_f="34578" txt_i="22212" txt_f="22299">The CALGB 8921 was also a phase 2 study in which a maximal permissible dose of 100 mg/m</offsets><sup><offsets xml_i="34583" xml_f="34584" txt_i="22299" txt_f="22300">2</offsets></sup><offsets xml_i="34590" xml_f="34809" txt_i="22300" txt_f="22519"> was administered subcutaneously. Sixty-seven patients were enrolled (included CMML). Overall response was 52% with CR observed in 12%, PR in 12% and 28% HI. In the phase three randomized controlled trial, CALGB 9221, (</offsets><xref ref-type="bibr" rid="b58"><offsets xml_i="34841" xml_f="34861" txt_i="22519" txt_f="22539">Silverman et al 2002</offsets></xref><offsets xml_i="34868" xml_f="35060" txt_i="22539" txt_f="22731">) patients were randomized to 5 Azacytidine or a supportive care arm. Crossover was permitted 4 months later if the disease worsened. The patients received 5-Azacytidine at a dosage of 75 mg/m</offsets><sup><offsets xml_i="35065" xml_f="35066" txt_i="22731" txt_f="22732">2</offsets></sup><offsets xml_i="35072" xml_f="36360" txt_i="22732" txt_f="24017">/day subcutaneously for 7 days of a 28-day cycle with a minimum of four courses planned. 3 additional cycles were administered to responding patients, whereas those with partial responses continued 5 Azacytidine till complete response or relapse. Overall responses occurred in 60% with 7% achieving CR, 16% PR, and 37% HI (HI). Responses of 47% were seen in the crossover patients compared with 5% HI only in the supportive care arm. Additionally, time to progression to AML was significantly delayed (21 versus 12 months). After 6 months of treatment significantly less (3%) patients treated with Azacytidine transformed to AML when compared to those in the supportive care arm (3% vs 24%, p&lt;0.0001). The median duration of response was 15 months. Median survival for patients on study for 6 months was 18 months (from initial randomisation) compared to 14 months for those who crossed over and 11 months for those who did not crossover. The main side effect was worsening of cytopenias (grade 3–4 hematological toxicity with 43% leucopenia and 58% granulocytopenia, 52% thrombocytopenia) although most patients recovered their blood counts by 4 weeks. Notably no case of bone marrow aplasia following Azacytidine occurred. Infection related to treatment occurred in 20% of patients (</offsets><xref ref-type="bibr" rid="b58"><offsets xml_i="36392" xml_f="36412" txt_i="24017" txt_f="24037">Silverman et al 2002</offsets></xref><offsets xml_i="36419" xml_f="36499" txt_i="24037" txt_f="24117">). Despite this, the responses were accompanied by an improved quality of life (</offsets><xref ref-type="bibr" rid="b41"><offsets xml_i="36531" xml_f="36551" txt_i="24117" txt_f="24137">Kornblith et al 2002</offsets></xref><offsets xml_i="36558" xml_f="37071" txt_i="24137" txt_f="24650">). Sequential cytogenetic studies carried out on a subgroup of these patients showed that 8% of patients with clonal cytogenetics achieved cytogenetic remissions. 13% of patients with initial abnormal cytogenetics developed additional clones, however 60% of patients with clonal abnormalities developed HI despite the presence of an abnormal clone. Additional cytogenetic abnormalities developed in those with normal cytogenetics in 36% of patients (the same rate as for MDS being treated with other modalities) (</offsets><xref ref-type="bibr" rid="b49"><offsets xml_i="37103" xml_f="37121" txt_i="24650" txt_f="24668">Najfeld et al 2002</offsets></xref><offsets xml_i="37128" xml_f="37384" txt_i="24668" txt_f="24924">). This study remains the only randomized controlled study, however a confirmatory trial comparing patients with MDS (IPSS score 1.5 or greater) treated with Azacytidine versus conventional care or best supportive care is ongoing and due to report in 2006.</offsets></p></sec><sec><title><offsets xml_i="37406" xml_f="37446" txt_i="24926" txt_f="24966">Cytogenetics and response to Azacytidine</offsets></title><p><xref ref-type="bibr" rid="b48"><offsets xml_i="37489" xml_f="37509" txt_i="24967" txt_f="24987">Najfeld et al (2004)</offsets></xref><offsets xml_i="37516" xml_f="37769" txt_i="24987" txt_f="25240"> reported that patients with normal cytogenetics appeared to have a superior response to Azacytidine. Amongst 26 evaluable patients treated at King’s College Hospital, 7 patients achieved CR. 5 of these had a chromosome 7 abnormality and 2 a trisomy 8 (</offsets><xref ref-type="bibr" rid="b55"><offsets xml_i="37801" xml_f="37815" txt_i="25240" txt_f="25254">Raj et al 2005</offsets></xref><offsets xml_i="37822" xml_f="38250" txt_i="25254" txt_f="25682">). The response rate for patients with a sole chromosome 7 abnormality was 80% (4/5 patients treated) and patients with monosomy 7 have durable remissions whereas patients with Trisomy 8 experienced an early relapse in their cytopenias. Interestingly this was not accompanied by an increase in BM blasts. These observations suggest that patients with chromosome 7 abnormalities may particularly benefit from Azacytidine therapy.</offsets></p></sec></sec><sec><title><offsets xml_i="38278" xml_f="38295" txt_i="25685" txt_f="25702">Clinical response</offsets></title><p><offsets xml_i="38306" xml_f="38467" txt_i="25703" txt_f="25864">The clinical response usually follows a typical pattern with an increase in platelet counts being the first response. Increases of platelet counts above 100 × 10</offsets><sup><offsets xml_i="38472" xml_f="38473" txt_i="25864" txt_f="25865">9</offsets></sup><offsets xml_i="38479" xml_f="39177" txt_i="25865" txt_f="26563">/L (usually 200– 700) are followed by an increase in the hemoglobin levels. These responses are usually accompanied by a reduction in BM blasts to less than 5%. Patients often achieve blast reduction to less than 5% even if this is not accompanied by an improvement in blood counts. In 8 patients BM aspirates were carried out at Day 7 of the first cycle of treatment and were often hypocellular with an increased apoptosis (unpublished data). BM biopsies following Azacytidine retain the dyplastic features of MDS despite the normal distribution of erythroid islands and a reduction in blasts. An increase in lymphoid follicles and lymphocytes may occur and a marked eosinophilia is also evident (</offsets><xref ref-type="fig" rid="fig4"><offsets xml_i="39209" xml_f="39217" txt_i="26563" txt_f="26571">Figure 4</offsets></xref><offsets xml_i="39224" xml_f="39226" txt_i="26571" txt_f="26573">).</offsets></p><fig id="fig4" position="float"><label><offsets xml_i="39269" xml_f="39277" txt_i="26574" txt_f="26582">Figure 4</offsets></label><caption><p><offsets xml_i="39297" xml_f="39441" txt_i="26582" txt_f="26726">Bone marrow responses to 5-Azacytidine.The bone marrow trephine biopsies from a patient with monosomy 7 were stained with hamatoxylin and eosin.</offsets></p><p><offsets xml_i="39448" xml_f="39743" txt_i="26727" txt_f="27022">(A) prior to 5-Azacytidine, showing a normocellular marrow with dysplastic megakaryocytes (arrow) and no erythropoiesis. (B) Post 5-Azacytidine in cytogenetic remission the bone marrow was normocellular and erythroid islands (arrow) were present. Marked eosinophilia post Azacytidine is evident.</offsets></p></caption><graphic xlink:href="tcrm0204-377-04"></graphic></fig></sec><sec><title><offsets xml_i="39829" xml_f="39859" txt_i="27024" txt_f="27054">Relapses following Azacytidine</offsets></title><p><offsets xml_i="39870" xml_f="39978" txt_i="27055" txt_f="27163">Patients who relapse following complete remission are often at a different stage of the disease at relapse (</offsets><xref ref-type="bibr" rid="b10"><offsets xml_i="40010" xml_f="40027" txt_i="27163" txt_f="27180">Cheson et al 2000</offsets></xref><offsets xml_i="40034" xml_f="40563" txt_i="27180" txt_f="27709">). For example, in our cohort of patients with Trisomy 8, relapses were manifest by neutropenia, followed by thrombocytopenia and then anemia. These relapses were unaccompanied by an increase in BM blast percentage or cytogenetic abnormality, however cytopenias prevented further administration of Azacytidine then resulting in a frank relapse at a median of 4 months after stopping therapy. These cytopenic relapses may represent an earlier stage of the disease ie, refractory cytopenia or a manifestation of dysplastic relapse.</offsets></p></sec><sec><title><offsets xml_i="40585" xml_f="40593" txt_i="27711" txt_f="27719">Toxicity</offsets></title><p><offsets xml_i="40604" xml_f="40706" txt_i="27720" txt_f="27822">Myelosuppression is the commonest toxicity but is difficult to evaluate due to antecedent cytopenias. </offsets><xref ref-type="bibr" rid="b58"><offsets xml_i="40738" xml_f="40760" txt_i="27822" txt_f="27844">Silverman et al (2002)</offsets></xref><offsets xml_i="40767" xml_f="40881" txt_i="27844" txt_f="27958"> assessed myelosuppression on the relative changes in peripheral blood counts compared with those at study entry (</offsets><xref ref-type="bibr" rid="b58"><offsets xml_i="40913" xml_f="40933" txt_i="27958" txt_f="27978">Silverman et al 2002</offsets></xref><offsets xml_i="40940" xml_f="41486" txt_i="27978" txt_f="28524">). Grade 3 toxicity was defined as a decrease of 50%–74% whereas grade 4 constituted 75% or greater reduction in peripheral blood counts. Grade 3 or 4 leucopenia occurs in 43%, granulocytopenia in 58%, and thrombocytopenia in 52% of patients. Nausea or vomiting occured in 4% and constipation (either due to the drug or concomitant anti-emetics) occurred in 31% of patients. Injection site erythrema/reaction is common, occurring in 27% in our experience. Rarely gout and acute renal failure may ensue. Serum sickness like illness occurs rarely (</offsets><xref ref-type="bibr" rid="b28"><offsets xml_i="41518" xml_f="41533" txt_i="28524" txt_f="28539">Gryn et al 2002</offsets></xref><offsets xml_i="41540" xml_f="41690" txt_i="28539" txt_f="28689">). Abnormal liver function tests occur in 7% and generalised weakness, muscle tenderness and lethargy occur in 3% (Azacytidine Investigators brochure)</offsets></p></sec><sec><title><offsets xml_i="41712" xml_f="41738" txt_i="28691" txt_f="28717">Mechanism of action in MDS</offsets></title><p><offsets xml_i="41749" xml_f="41960" txt_i="28718" txt_f="28929">Although the various mechanisms by which the drug works are known, definitive proof that its effects in MDS are either due to demethylation of several key genes or to its cytotoxic action remain unclear. Whilst </offsets><italic><offsets xml_i="41968" xml_f="41974" txt_i="28929" txt_f="28935">CDKN2B</offsets></italic><offsets xml_i="41983" xml_f="42142" txt_i="28935" txt_f="29094"> may be an important gene in the pathogenesis of progression of early MDS to more aggressive phases of the disease, it is often not hypermethylated in the CD34</offsets><sup><offsets xml_i="42147" xml_f="42148" txt_i="29094" txt_f="29095">+</offsets></sup><offsets xml_i="42154" xml_f="42162" txt_i="29095" txt_f="29103"> or CD33</offsets><sup><offsets xml_i="42167" xml_f="42168" txt_i="29103" txt_f="29104">+</offsets></sup><offsets xml_i="42174" xml_f="42264" txt_i="29104" txt_f="29194"> BM cells but appears to be hypermethylated in the lymphocytes of some patients with MDS (</offsets><xref ref-type="bibr" rid="b36"><offsets xml_i="42296" xml_f="42311" txt_i="29194" txt_f="29209">John et al 2005</offsets></xref><offsets xml_i="42318" xml_f="42391" txt_i="29209" txt_f="29282">). Moreover some of the patients who achieved CR are unmethylated at the </offsets><italic><offsets xml_i="42399" xml_f="42405" txt_i="29282" txt_f="29288">CDKN2B</offsets></italic><offsets xml_i="42414" xml_f="42544" txt_i="29288" txt_f="29418"> promoter suggesting demethylation of this gene is not critical in the responses to Azacytidine in at least a subset of patients (</offsets><xref ref-type="bibr" rid="b33"><offsets xml_i="42576" xml_f="42591" txt_i="29418" txt_f="29433">Issa et al 2004</offsets></xref><offsets xml_i="42598" xml_f="42600" txt_i="29433" txt_f="29435">; </offsets><xref ref-type="bibr" rid="b54"><offsets xml_i="42632" xml_f="42646" txt_i="29435" txt_f="29449">Raj et al 2004</offsets></xref><offsets xml_i="42653" xml_f="42655" txt_i="29449" txt_f="29451">).</offsets></p><p><offsets xml_i="42662" xml_f="42909" txt_i="29452" txt_f="29699">Previous studies have shown that apoptosis was treatment with Azacytidine. Increased apoptosis correlated increased in early MDS (RA, RARS) but decreased with with best response in patients whereas non-responders did disease progression (RAEB-t) (</offsets><xref ref-type="bibr" rid="b52"><offsets xml_i="42941" xml_f="42958" txt_i="29699" txt_f="29716">Parker et al 2000</offsets></xref><offsets xml_i="42965" xml_f="43245" txt_i="29716" txt_f="29996">). not show an increase in apoptosis. Therefore in advanced Preliminary results show that patients with high risk MDS MDS, reversal of the low apoptosis by Azacytidine may had low apoptosis prior to treatment that increased following cause disease regression to an earlier stage (</offsets><xref ref-type="bibr" rid="b55"><offsets xml_i="43277" xml_f="43291" txt_i="29996" txt_f="30010">Raj et al 2005</offsets></xref><offsets xml_i="43298" xml_f="43300" txt_i="30010" txt_f="30012">).</offsets></p></sec><sec><title><offsets xml_i="43322" xml_f="43341" txt_i="30014" txt_f="30033">Duration of therapy</offsets></title><p><offsets xml_i="43352" xml_f="44490" txt_i="30034" txt_f="31172">The CALGB 9221 scheduled Azacytidine for 4 cycles, if CR was achieved a further 3 cycles were administered. For patients showing PR/HI further courses were allowed till either CR or relapse occurred. However relapses in responses achieved may occur once the drug is stopped. The median duration of response was 15 months from randomization. The current recommendation is to use the drug at the same schedule of dosing indefinitely once CR is achieved. There is limited data on the precise role of maintenance therapy. In our experience patients often develop neutropenia accompanied by reduction in the bone marrow cellularity that necessitates increasing the interval between the courses of treatment. Re-treatment of 22 patients previously treated with decitabine led to one complete remission, 2 PR’s and 7 HI. The median duration of response was 4 months (1–16 months) suggesting that the quality and length of response to re-treatment was poorer than the original response. Thus patients probably need to continue treatment for prolonged periods of time, the dose and scheduling being guided by BM cellularity and neutrophil recovery</offsets></p></sec><sec><title><offsets xml_i="44512" xml_f="44529" txt_i="31174" txt_f="31191">Other MTIs in MDS</offsets></title><p><offsets xml_i="44540" xml_f="44787" txt_i="31192" txt_f="31439">Azacytidine is the prodrug for decitabine that is 10 times more potent in inhibiting DNMT. Decitabine is incorporated only into DNA whereas 5-Azacytidine is incorporated into both RNA and DNA. In phase II studies, continuous infusion of 40–50 mg/m</offsets><sup><offsets xml_i="44792" xml_f="44793" txt_i="31439" txt_f="31440">2</offsets></sup><offsets xml_i="44799" xml_f="45017" txt_i="31440" txt_f="31658">/day for 3 days was effective in inducing responses in 15/29 (52%) patients with MDS. Grade III/IV neutropenia and associated complications were common. A multicenter phase II study of decitabine at a dosage of 45 mg/m</offsets><sup><offsets xml_i="45022" xml_f="45023" txt_i="31658" txt_f="31659">2</offsets></sup><offsets xml_i="45029" xml_f="45332" txt_i="31659" txt_f="31962"> over 3–4 hours daily for 3 days at 6 weekly intervals for 4 courses in patients who had a CR in the first two courses or a maximum of 6 courses for partial responders. Overall responses were higher for the IPSS high-risk group with 64% versus 49% overall. The median duration of response was 31 weeks (</offsets><xref ref-type="bibr" rid="b68"><offsets xml_i="45364" xml_f="45384" txt_i="31962" txt_f="31982">Wijermans et al 2000</offsets></xref><offsets xml_i="45391" xml_f="45531" txt_i="31982" txt_f="32122">). 19/61 (31%) patients with cytogenetic abnormalities obtained a complete cytogenetic response that was associated with improved survival (</offsets><xref ref-type="bibr" rid="b43"><offsets xml_i="45563" xml_f="45581" txt_i="32122" txt_f="32140">Lubbert et al 2001</offsets></xref><offsets xml_i="45588" xml_f="45617" txt_i="32140" txt_f="32169">). Low dose decitabine 5 mg/m</offsets><sup><offsets xml_i="45622" xml_f="45623" txt_i="32169" txt_f="32170">2</offsets></sup><offsets xml_i="45629" xml_f="45642" txt_i="32170" txt_f="32183">/day, 10 mg/m</offsets><sup><offsets xml_i="45647" xml_f="45648" txt_i="32183" txt_f="32184">2</offsets></sup><offsets xml_i="45654" xml_f="45667" txt_i="32184" txt_f="32197">/day, 15 mg/m</offsets><sup><offsets xml_i="45672" xml_f="45673" txt_i="32197" txt_f="32198">2</offsets></sup><offsets xml_i="45679" xml_f="45695" txt_i="32198" txt_f="32214">/day, or 20 mg/m</offsets><sup><offsets xml_i="45700" xml_f="45701" txt_i="32214" txt_f="32215">2</offsets></sup><offsets xml_i="45707" xml_f="45834" txt_i="32215" txt_f="32342">/day intravenously over one hour for 5/7 days a week for 2 weeks was well tolerated with best responses observed in the 15 mg/m</offsets><sup><offsets xml_i="45839" xml_f="45840" txt_i="32342" txt_f="32343">2</offsets></sup><offsets xml_i="45846" xml_f="45852" txt_i="32343" txt_f="32349">/day (</offsets><xref ref-type="bibr" rid="b33"><offsets xml_i="45884" xml_f="45899" txt_i="32349" txt_f="32364">Issa et al 2004</offsets></xref><offsets xml_i="45906" xml_f="46941" txt_i="32364" txt_f="33399">). Whilst the criteria for responses varied in the initial trials, reanalysis of the responses of all 177 patients treated in the three European phase II studies (median age 70 years) by the International Working Group (IWG) criteria confirmed the efficacy of decitabine in achieving a CR in 24% of patients and an overall response rate of 49%. The median duration of response was 36 weeks with a median survival of 15 months. 18% of patients progressed to leukemia during treatment. These results are comparable with those for 5-Azacytidine. Age, sex, FAB subgroup, IPSS risk group, lactate dehydrogenase (LDH) and cytogenetics were not predictive of response although patients with high risk cytogenetics according to the IPSS score showed a better overall survival than those with intermediate risk abnormalities. As the IPSS score of patients at diagnosis was not available, no comparison between predicted survival and actual survival following decitabine was possible to see if a particular subgroup benefited from this therapy (</offsets><xref ref-type="bibr" rid="b69"><offsets xml_i="46973" xml_f="46993" txt_i="33399" txt_f="33419">Wijermans et al 2005</offsets></xref><offsets xml_i="47000" xml_f="47489" txt_i="33419" txt_f="33908">). 61/115 patients treated with decitabine had clonal cytogenetics and 31% of these achieved a cytogenetic response at a median of 3 cycles of decitabine therapy (18 weeks). The median duration of response was 7.5 months (3–15 months). 60% (3/5) of patients with a low IPSS score, 20% (6/30) with intermediate risk and 38% (10/26) with high-risk cytogenetics achieved cytogenetic remissions. These translated into a longer survival if complete cytogenetic remission was achieved (p=0.02) (</offsets><xref ref-type="bibr" rid="b43"><offsets xml_i="47521" xml_f="47539" txt_i="33908" txt_f="33926">Lubbert et al 2001</offsets></xref><offsets xml_i="47546" xml_f="47732" txt_i="33926" txt_f="34112">). Cytogenetic remissions in response to decitabine preceded genome wide demethylation of genes suggesting that a cytotoxic effect or cell death of the abnormal clone led to remissions (</offsets><xref ref-type="bibr" rid="b47"><offsets xml_i="47764" xml_f="47779" txt_i="34112" txt_f="34127">Mund et al 2005</offsets></xref><offsets xml_i="47786" xml_f="47965" txt_i="34127" txt_f="34303">). Increased platelet counts after the first course of decitabine therapy occurred in 58% of thrombocytopenic patients and significantly (p&lt;0.0001) predicted overall survival (</offsets><xref ref-type="bibr" rid="b65"><offsets xml_i="47997" xml_f="48021" txt_i="34303" txt_f="34327">van den Bosch et al 2004</offsets></xref><offsets xml_i="48028" xml_f="48184" txt_i="34327" txt_f="34483">). Myelosuppression leading to fever and sepsis occurred in 20% of patients in the phase II randomized study with the treatment related mortality being 7% (</offsets><xref ref-type="bibr" rid="b68"><offsets xml_i="48216" xml_f="48236" txt_i="34483" txt_f="34503">Wijermans et al 2000</offsets></xref><offsets xml_i="48243" xml_f="48407" txt_i="34503" txt_f="34667">). Abnormal liver function tests were seen in 16% of patients, grade III cardiovascular problems occurred in 8% of patients and were mostly unrelated to decitabine.</offsets></p></sec><sec><title><offsets xml_i="48429" xml_f="48448" txt_i="34669" txt_f="34688">Combination therapy</offsets></title><p><offsets xml_i="48459" xml_f="48657" txt_i="34689" txt_f="34887">Although the DNMT inhibitors are effective in myeloid leukemia’s and MDS, they are limited by low response rates (23% CR and PR) and a short median duration of response (15 months for Azacytidine) (</offsets><xref ref-type="bibr" rid="b58"><offsets xml_i="48689" xml_f="48709" txt_i="34887" txt_f="34907">Silverman et al 2002</offsets></xref><offsets xml_i="48716" xml_f="48718" txt_i="34907" txt_f="34909">).</offsets></p><p><offsets xml_i="48725" xml_f="48923" txt_i="34910" txt_f="35108">Combination chemotherapy has led to improved CR rates in AML. Similarly, targeting complementary biological pathways with synergistic drugs, could improve the response rates and duration with MTI’s.</offsets></p><p><offsets xml_i="48930" xml_f="49419" txt_i="35109" txt_f="35598">Other therapies being developed for MDS include, histone deacetylase inhibitors (HDACi), tumour necrosis factor (TNF) antagonists including etanercept and infliximab, farnesyl transferase inhibitors (tipifarnib and lonafarnib) arsenic trioxide, retinoids, lenalidomide, signal transduction inhibitors bevacizumab, SCIO469 and PTK787, and the glutathione S-transferase PI inhibitor TLK199. The combination of Azacytidine with HDACi is the furthest in clinical trials and is discussed below.</offsets></p><sec><title><offsets xml_i="49435" xml_f="49450" txt_i="35599" txt_f="35614">HDAC inhibitors</offsets></title><p><offsets xml_i="49461" xml_f="50519" txt_i="35615" txt_f="36673">DNA is packaged in chromatin that is made up of an octamer of histones. Acetylation of lysine residues on histone tails adds a net negative charge that results in chromatin being in an open configuration (euchromatin) whereas removal of acetyl groups by histone deacetylases (HDAC‘s) results in chromatin being held in a closed configuration (heterochromatin), preventing transcription of genes. Methylation of gene promoters acts in conjunction with histone deacetylation in the silencing of genes. Methylated promoters recruit transcriptional repression complexes that include HDAC’s via specific methyl-binding proteins leading to heterochromatin being associated with that gene. Therefore inducing re-expression of epigenetically silenced genes could be achieved by either demethylation of DNA or acetylation of chromatin. In vitro studies have shown that HDACi are unable to reactivate the expression of heavily methylated genes. However the addition of HDACi following exposure to DNMT inhibitors leads to synergistic reactivation of methylated genes (</offsets><xref ref-type="bibr" rid="b9"><offsets xml_i="50550" xml_f="50568" txt_i="36673" txt_f="36691">Cameron et al 1999</offsets></xref><offsets xml_i="50575" xml_f="50646" txt_i="36691" txt_f="36762">). There are five main classes of HDAC inhibitors (reviewed by Gore in </offsets><xref ref-type="bibr" rid="b46"><offsets xml_i="50678" xml_f="50694" txt_i="36762" txt_f="36778">Mufti et al 2003</offsets></xref><offsets xml_i="50701" xml_f="50836" txt_i="36778" txt_f="36913">). Of these, Valproic acid and MS275 in combination with MTI’s decitabine and Azacytidine respectively are in phase I clinical trials (</offsets><xref ref-type="bibr" rid="b25"><offsets xml_i="50868" xml_f="50877" txt_i="36913" txt_f="36922">Gore 2005</offsets></xref><offsets xml_i="50884" xml_f="50978" txt_i="36922" txt_f="37016">). Azacytidine combined sequentially with sodium phenylbutyrate (a HDACi) when used at 50 mg/m</offsets><sup><offsets xml_i="50983" xml_f="50984" txt_i="37016" txt_f="37017">2</offsets></sup><offsets xml_i="50990" xml_f="51055" txt_i="37017" txt_f="37082"> for 10 days (cohort A n=8), or 14 days (cohort B n=3) or 25 mg/m</offsets><sup><offsets xml_i="51060" xml_f="51061" txt_i="37082" txt_f="37083">2</offsets></sup><offsets xml_i="51067" xml_f="51570" txt_i="37083" txt_f="37586"> for 14 days (n=5) followed by 375 mg/kg daily continuous infusion of phenylbutyrate for 7 days led to clinical responses in all three cohorts. Cohort B experienced dose limiting toxicity of prolonged myelosuppression (greater than 14 days) in 2/3 patients however even this cohort had HI (1 HI-platelet and neutrophil major, and 1 HI-platelet major). Cohort A experienced CR in 3/8 and PR in 1/8 patients whereas cohort C developed HI-neutrophil major in 2 patients and HI-platelet major in 1 patient (</offsets><xref ref-type="bibr" rid="b26"><offsets xml_i="51602" xml_f="51617" txt_i="37586" txt_f="37601">Gore et al 2004</offsets></xref><offsets xml_i="51624" xml_f="51886" txt_i="37601" txt_f="37863">). This combination appears promising with doses of Azacytidine equivalent to or lower than that used in the CALGB trials. Further studies are necessary to confirm whether the addition of HDACi result in increased response rates and/or prolongation of responses.</offsets></p></sec></sec><sec><title><offsets xml_i="51914" xml_f="51930" txt_i="37866" txt_f="37882">Future direction</offsets></title><p><offsets xml_i="51941" xml_f="53344" txt_i="37883" txt_f="39286">Azacytidine induces prolonged complete remissions in up to 25% of patients. Overall, half the patients treated derive a clinically meaningful response in terms of transfusion independence and or blast cell reduction. This is associated with an improved quality of life. Patients with monosomy 7 are particularly responsive to treatment but this need confirmation in larger trials to enable selection of patients who would benefit maximally. Despite its universal demethylating and cytotoxic effects some patients do not respond. Factors responsible for this may include inadequate plasma levels of drug. Additionally some patients achieving CR relapse with cytopenias and identifying these patients and the reasons for this will enable modifications in the dosing regime and rational synergistic combination therapy with drugs such as HDACi. The identification of target genes and mechanisms by which the drug act are important as a means of monitoring responses to this therapy. Azacytidine as salvage therapy for relapsed AML with chromosome 7 abnormalities, maintenance chemotherapy for AML and in pre-transplant conditioning regimes are areas that are being explored in clinical trials. Epigenetic therapies such as Azacytidine have ushered in a new era in the management of MDS. We are at the beginning of understanding how to optimally use this group of agents in order to achieve maximal benefit.</offsets></p></sec></body><back><ref-list><title>References</title><ref id="b1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahuja</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Mohan</surname><given-names>AL</given-names></name><etal></etal></person-group><article-title>Aging and DNA methylation in colorectal mucosa and cancer</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>5489</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">9850084</pub-id></citation></ref><ref id="b2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amanullah</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>B</given-names></name><name><surname>Liebermann</surname><given-names>DA</given-names></name></person-group><article-title>Deregulated E2F-1 blocks terminal differentiation and loss of leukemogenicity of M1 myeloblastic leukemia cells without abrogating induction of p15(INK4B) and p16(INK4A)</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>475</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">10887108</pub-id></citation></ref><ref id="b3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antequera</surname><given-names>F</given-names></name><name><surname>Boyes</surname><given-names>J</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><article-title>High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines</article-title><source>Cell</source><year>1990</year><volume>62</volume><fpage>503</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">1974172</pub-id></citation></ref><ref id="b4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aul</surname><given-names>C</given-names></name><name><surname>Germing</surname><given-names>U</given-names></name><name><surname>Gattermann</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Increasing incidence of myelodysplastic syndromes: real or fictitious?</article-title><source>Leuk Res</source><year>1998</year><volume>22</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">9585086</pub-id></citation></ref><ref id="b5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>JM</given-names></name><name><surname>Catovsky</surname><given-names>D</given-names></name><name><surname>Daniel</surname><given-names>MT</given-names></name><etal></etal></person-group><article-title>Proposals for the classification of the myelodysplastic syndromes</article-title><source>Br J Haematol</source><year>1982</year><volume>51</volume><fpage>189</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">6952920</pub-id></citation></ref><ref id="b6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhagwat</surname><given-names>AS</given-names></name><name><surname>Roberts</surname><given-names>RJ</given-names></name></person-group><article-title>Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12</article-title><source>J Bacteriol</source><year>1987</year><volume>169</volume><fpage>1537</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">2435706</pub-id></citation></ref><ref id="b7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>A</given-names></name></person-group><article-title>DNA methylation patterns and epigenetic memory</article-title><source>Genes Dev</source><year>2002</year><volume>16</volume><fpage>6</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">11782440</pub-id></citation></ref><ref id="b8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>AP</given-names></name><name><surname>Taggart</surname><given-names>MH</given-names></name><name><surname>Smith</surname><given-names>BA</given-names></name></person-group><article-title>Methylated and unmethylated DNA compartments in the sea urchin genome</article-title><source>Cell</source><year>1979</year><volume>17</volume><fpage>889</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">487434</pub-id></citation></ref><ref id="b9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>EE</given-names></name><name><surname>Bachman</surname><given-names>KE</given-names></name><name><surname>Myohanen</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer</article-title><source>Nat Genet</source><year>1999</year><volume>21</volume><fpage>103</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9916800</pub-id></citation></ref><ref id="b10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheson</surname><given-names>BD</given-names></name><name><surname>Bennett</surname><given-names>JM</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Report of an international working group to standardize response criteria for myelodysplastic syndromes</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>3671</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11090046</pub-id></citation></ref><ref id="b11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>DH</given-names></name><name><surname>Andersen</surname><given-names>MK</given-names></name><name><surname>Pedersen-Bjergaard</surname><given-names>J</given-names></name></person-group><article-title>Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>1813</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">12970781</pub-id></citation></ref><ref id="b12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christman</surname><given-names>JK</given-names></name></person-group><article-title>5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5483</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">12154409</pub-id></citation></ref><ref id="b13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corn</surname><given-names>PG</given-names></name><name><surname>Smith</surname><given-names>BD</given-names></name><name><surname>Ruckdeschel</surname><given-names>ES</given-names></name><etal></etal></person-group><article-title>E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>4243</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11106238</pub-id></citation></ref><ref id="b14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Creusot</surname><given-names>F</given-names></name><name><surname>Acs</surname><given-names>G</given-names></name><name><surname>Christman</surname><given-names>JK</given-names></name></person-group><article-title>Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine</article-title><source>J Biol Chem</source><year>1982</year><volume>257</volume><fpage>2041</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">6173384</pub-id></citation></ref><ref id="b15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dao</surname><given-names>MA</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name><name><surname>Nolta</surname><given-names>JA</given-names></name></person-group><article-title>Reduction in levels of the cyclindependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>13006</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">9789031</pub-id></citation></ref><ref id="b16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delgado</surname><given-names>S</given-names></name><name><surname>Gomez</surname><given-names>M</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Initiation of DNA replication at CpG islands in mammalian chromosomes</article-title><source>Embo J</source><year>1998</year><volume>17</volume><fpage>2426</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">9545253</pub-id></citation></ref><ref id="b17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhodapkar</surname><given-names>M</given-names></name><name><surname>Grill</surname><given-names>J</given-names></name><name><surname>Lust</surname><given-names>JA</given-names></name></person-group><article-title>Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes</article-title><source>Leuk Res</source><year>1995</year><volume>19</volume><fpage>719</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">7500648</pub-id></citation></ref><ref id="b18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>HG</given-names></name></person-group><article-title>Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells</article-title><source>Leukemia</source><year>1998</year><volume>12</volume><fpage>845</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">9639410</pub-id></citation></ref><ref id="b19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Corn</surname><given-names>PG</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><etal></etal></person-group><article-title>A gene hypermethylation profile of human cancer</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3225</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11309270</pub-id></citation></ref><ref id="b20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frommer</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>LE</given-names></name><name><surname>Millar</surname><given-names>DS</given-names></name><etal></etal></person-group><article-title>A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands</article-title><source>Proc Natl Acad Sci U S A</source><year>1992</year><volume>89</volume><fpage>1827</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">1542678</pub-id></citation></ref><ref id="b21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>MJ</given-names></name><name><surname>Martinez-Delgado</surname><given-names>B</given-names></name><name><surname>Cebrian</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin’s and CD30-Positive non-Hodgkin’s lymphomas</article-title><source>Am J Pathol</source><year>2002</year><volume>161</volume><fpage>1007</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12213729</pub-id></citation></ref><ref id="b22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gardiner-Garden</surname><given-names>M</given-names></name><name><surname>Frommer</surname><given-names>M</given-names></name></person-group><article-title>CpG islands in vertebrate genomes</article-title><source>J Mol Biol</source><year>1987</year><volume>196</volume><fpage>261</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">3656447</pub-id></citation></ref><ref id="b23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Germing</surname><given-names>U</given-names></name><name><surname>Gattermann</surname><given-names>N</given-names></name><name><surname>Strupp</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients</article-title><source>Leuk Res</source><year>2000</year><volume>24</volume><fpage>983</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11077111</pub-id></citation></ref><ref id="b24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glover</surname><given-names>AB</given-names></name><name><surname>Leyland-Jones</surname><given-names>BR</given-names></name><name><surname>Chun</surname><given-names>HG</given-names></name><etal></etal></person-group><article-title>Azacitidine: 10 years later</article-title><source>Cancer Treat Rep</source><year>1987</year><volume>71</volume><fpage>737</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">2440570</pub-id></citation></ref><ref id="b25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gore</surname><given-names>SD</given-names></name></person-group><article-title>Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies</article-title><source>Nat Clin Pract Oncol</source><year>2005</year><volume>2</volume><issue>Suppl 1</issue><fpage>S30</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16341238</pub-id></citation></ref><ref id="b26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gore</surname><given-names>SD</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Dauses</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-Azacitidine and sodium phenylbutyrate [abstract]</article-title><source>Blood</source><year>2004</year><volume>104</volume><issue>11</issue><fpage>469</fpage></citation></ref><ref id="b27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>LeBeau</surname><given-names>MM</given-names></name><etal></etal></person-group><article-title>International scoring system for evaluating prognosis in myelodysplastic syndromes</article-title><source>Blood</source><year>1997</year><volume>89</volume><fpage>2079</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">9058730</pub-id></citation></ref><ref id="b28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gryn</surname><given-names>J</given-names></name><name><surname>Zeigler</surname><given-names>ZR</given-names></name><name><surname>Shadduck</surname><given-names>RK</given-names></name><etal></etal></person-group><article-title>Treatment of myelodysplastic syndromes with 5-azacytidine</article-title><source>Leuk Res</source><year>2002</year><volume>26</volume><fpage>893</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12163049</pub-id></citation></ref><ref id="b29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haaf</surname><given-names>T</given-names></name></person-group><article-title>The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: Implications for methylation-associated cellular processes</article-title><source>Pharmacol Ther</source><year>1995</year><volume>65</volume><fpage>19</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">7536332</pub-id></citation></ref><ref id="b30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heaney</surname><given-names>ML</given-names></name><name><surname>Golde</surname><given-names>DW</given-names></name></person-group><article-title>Myelodysplasia</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1649</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">10341278</pub-id></citation></ref><ref id="b31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Latif</surname><given-names>F</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma</article-title><source>PNAS</source><year>1994</year><volume>91</volume><fpage>9700</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7937876</pub-id></citation></ref><ref id="b32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>AY</given-names></name><name><surname>Pagliuca</surname><given-names>A</given-names></name><name><surname>Kenyon</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>1616</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15059843</pub-id></citation></ref><ref id="b33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Issa</surname><given-names>JP</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Giles</surname><given-names>FJ</given-names></name><etal></etal></person-group><article-title>Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>1635</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">14604977</pub-id></citation></ref><ref id="b34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><article-title>Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals</article-title><source>Nat Genet</source><year>2003</year><volume>33</volume><issue>Suppl</issue><fpage>245</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">12610534</pub-id></citation></ref><ref id="b35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johan</surname><given-names>MF</given-names></name><name><surname>Goodeve</surname><given-names>AC</given-names></name><name><surname>Bowen</surname><given-names>DT</given-names></name><etal></etal></person-group><article-title>Promoter methylation of RASSFIA, SHP1 and SOCS1 genes in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) [abstract]</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>2999</fpage></citation></ref><ref id="b36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>A</given-names></name><name><surname>Raj</surname><given-names>K</given-names></name><name><surname>Mufti</surname><given-names>GJ</given-names></name><etal></etal></person-group><article-title>Lymphocytes but not CD34+ or CD33+ myeloid cells, of MDS have a hypermethylated CDKN2B promoter</article-title><source>Br J Haematol</source><year>2005</year><volume>129</volume><issue>Suppl 1</issue><fpage>6</fpage></citation></ref><ref id="b37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PA</given-names></name><name><surname>Taylor</surname><given-names>SM</given-names></name></person-group><article-title>Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells</article-title><source>Nucleic Acids Res</source><year>1981</year><volume>9</volume><fpage>2933</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">6169003</pub-id></citation></ref><ref id="b38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PA</given-names></name><name><surname>Taylor</surname><given-names>SM</given-names></name><name><surname>Wilson</surname><given-names>VL</given-names></name></person-group><article-title>Inhibition of DNA methylation by 5-azacytidine</article-title><source>Recent Results Cancer Res</source><year>1983</year><volume>84</volume><fpage>202</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">6189159</pub-id></citation></ref><ref id="b39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PL</given-names></name><name><surname>Veenstra</surname><given-names>GJ</given-names></name><name><surname>Wade</surname><given-names>PA</given-names></name><etal></etal></person-group><article-title>Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription</article-title><source>Nat Genet</source><year>1998</year><volume>19</volume><fpage>187</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">9620779</pub-id></citation></ref><ref id="b40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaminskas</surname><given-names>E</given-names></name><name><surname>Farrell</surname><given-names>AT</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><etal></etal></person-group><article-title>FDA drug approval summary: Azacitidine (5-azacytidine, VidazaTM) for injectable suspension</article-title><source>Oncologist</source><year>2005</year><volume>10</volume><fpage>176</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15793220</pub-id></citation></ref><ref id="b41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kornblith</surname><given-names>AB</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names><suffix>2nd</suffix></name><name><surname>Silverman</surname><given-names>LR</given-names></name><etal></etal></person-group><article-title>Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>2441</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12011121</pub-id></citation></ref><ref id="b42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Kopecky</surname><given-names>KJ</given-names></name><name><surname>Mohan</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>1077</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">10353741</pub-id></citation></ref><ref id="b43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lubbert</surname><given-names>M</given-names></name><name><surname>Wijermans</surname><given-names>P</given-names></name><name><surname>Kunzmann</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine</article-title><source>Br J Haematol</source><year>2001</year><volume>114</volume><fpage>349</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">11529854</pub-id></citation></ref><ref id="b44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>JR</given-names></name><name><surname>Vincent</surname><given-names>PC</given-names></name><name><surname>Clark</surname><given-names>SJ</given-names></name></person-group><article-title>Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>3730</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10446989</pub-id></citation></ref><ref id="b45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Chijiwa</surname><given-names>T</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>1172</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11222358</pub-id></citation></ref><ref id="b46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mufti</surname><given-names>G</given-names></name><name><surname>List</surname><given-names>AF</given-names></name><name><surname>Gore</surname><given-names>SD</given-names></name><etal></etal></person-group><article-title>Myelodysplastic syndrome</article-title><source>Hematology</source><year>2003</year><volume>2003</volume><fpage>176</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">14633782</pub-id></citation></ref><ref id="b47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mund</surname><given-names>C</given-names></name><name><surname>Hackanson</surname><given-names>B</given-names></name><name><surname>Stresemann</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>7086</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16103056</pub-id></citation></ref><ref id="b48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Najfeld</surname><given-names>V</given-names></name><name><surname>Scalise</surname><given-names>A</given-names></name><name><surname>Odchimer-Reissig</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>The modulating effect of Azacitidine (Aza C) on the cytogenetically tracked MDS clone impact survival [abstract]</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>1429</fpage></citation></ref><ref id="b49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Najfeld</surname><given-names>V</given-names></name><name><surname>Silverman</surname><given-names>LR</given-names></name><name><surname>Scalise</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Modulation of the cytogenetically abnormal myelodysplastic (MDS) clone by Azacitidine (Aza C) [abstract]</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>97a</fpage></citation></ref><ref id="b50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamaki</surname><given-names>T</given-names></name><name><surname>Bartram</surname><given-names>C</given-names></name><name><surname>Seriu</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes</article-title><source>Leuk Res</source><year>1997</year><volume>21</volume><fpage>235</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9111168</pub-id></citation></ref><ref id="b51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okano</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><etal></etal></person-group><article-title>DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development</article-title><source>Cell</source><year>1999</year><volume>99</volume><fpage>247</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">10555141</pub-id></citation></ref><ref id="b52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>JE</given-names></name><name><surname>Mufti</surname><given-names>GJ</given-names></name><name><surname>Rasool</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>3932</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11090080</pub-id></citation></ref><ref id="b53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quesnel</surname><given-names>B</given-names></name><name><surname>Guillerm</surname><given-names>G</given-names></name><name><surname>Vereecque</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression</article-title><source>Blood</source><year>1998</year><volume>91</volume><fpage>2985</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9531610</pub-id></citation></ref><ref id="b54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>K</given-names></name><name><surname>John</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>5-Azacytidine in the treatment of high risk myelodysplastic syndromes: clinical response can occur without demethylation of the CDKN2B, CDKN1A or TP73 gene promoters [abstract]</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>2369</fpage></citation></ref><ref id="b55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>KK</given-names></name><name><surname>John</surname><given-names>AM</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Early and sustained response to azacytidine in high-risk MDS patients with monosomy 7 correlates with increased apoptosis and not CDKN2B demethylation [abstract]</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>2530</fpage><pub-id pub-id-type="pmid">15933056</pub-id></citation></ref><ref id="b56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rudek</surname><given-names>MA</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Pharmacokinetics of 5-Azacitidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>3906</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15851763</pub-id></citation></ref><ref id="b57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Smiraglia</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>3226</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">11342453</pub-id></citation></ref><ref id="b58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>LR</given-names></name><name><surname>Demakos</surname><given-names>EP</given-names></name><name><surname>Peterson</surname><given-names>BL</given-names></name><etal></etal></person-group><article-title>Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>2429</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12011120</pub-id></citation></ref><ref id="b59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teofili</surname><given-names>L</given-names></name><name><surname>Martini</surname><given-names>M</given-names></name><name><surname>Di Mario</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>495</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11435325</pub-id></citation></ref><ref id="b60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teofili</surname><given-names>L</given-names></name><name><surname>Morosetti</surname><given-names>R</given-names></name><name><surname>Martini</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Expression of cyclindependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation</article-title><source>Exp Hematol</source><year>2000</year><volume>28</volume><fpage>519</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">10812241</pub-id></citation></ref><ref id="b61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tessema</surname><given-names>M</given-names></name><name><surname>Langer</surname><given-names>F</given-names></name><name><surname>Dingemann</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML)</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>910</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">12750705</pub-id></citation></ref><ref id="b62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tien</surname><given-names>HF</given-names></name><name><surname>Tang</surname><given-names>JH</given-names></name><name><surname>Tsay</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation</article-title><source>Br J Haematol</source><year>2001</year><volume>112</volume><fpage>148</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11167795</pub-id></citation></ref><ref id="b63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Kopecky</surname><given-names>KJ</given-names></name><name><surname>Toyota</surname><given-names>MO</given-names></name><etal></etal></person-group><article-title>Methylation profiling in acute myeloid leukemia</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>2823</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11313277</pub-id></citation></ref><ref id="b64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Hotta</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene</article-title><source>Leuk Lymphoma</source><year>1998</year><volume>32</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">10036997</pub-id></citation></ref><ref id="b65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Bosch</surname><given-names>J</given-names></name><name><surname>Lubbert</surname><given-names>M</given-names></name><name><surname>Verhoef</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes</article-title><source>Leuk Res</source><year>2004</year><volume>28</volume><fpage>785</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15203276</pub-id></citation></ref><ref id="b66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vardiman</surname><given-names>JW</given-names></name></person-group><article-title>The World Health Organisation (WHO) classification of the myeloid neoplasms</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2292</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">12239137</pub-id></citation></ref><ref id="b67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>JM</given-names></name></person-group><article-title>Epigenetics, mismatch repair genes and colorectal cancer</article-title><source>Ann R Coll Surg Engl</source><year>2005</year><volume>87</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15720901</pub-id></citation></ref><ref id="b68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijermans</surname><given-names>P</given-names></name><name><surname>Lubbert</surname><given-names>M</given-names></name><name><surname>Verhoef</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>956</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10694544</pub-id></citation></ref><ref id="b69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijermans</surname><given-names>PW</given-names></name><name><surname>Lubbert</surname><given-names>M</given-names></name><name><surname>Verhoef</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients</article-title><source>Ann Hematol</source><year>2005</year><volume>84</volume><issue>Suppl 13</issue><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16211386</pub-id></citation></ref></ref-list></back></article>